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Abstract

Interactions of mtFabH with its substrates and inhibitors reveal novel
mechanistic insights
By Sarbjot Singh Sachdeva, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
at Virginia Commonwealth University.
Virginia Commonwealth University, 2007
Major Director: Kevin A. Reynolds
Professor, Department of Medicinal Chemistry (former)
Professor and Chairman, Department of Chemistry, Portland State University (current)

Tuberculosis emerged from its grave to be one of the deadliest diseases of the
present time after recently developing a synergy with AIDS. A fatty acid condensing
enzyme-mtFabH has been proposed to connect the key processes involved in biosynthesis
of mycolic acids, an important component of mycobacterial cell wall. It condenses long
acyl Coenzymes A (CoA; up to C20CoA) with malonyl Acyl Carrier Protein (ACP) to
form the elongated β-ketoacyl-ACP which further undergoes rounds of elongation to
form mero-mycolate branch of mature mycolic acids. Owing to its proposed central
position in mycolic acid synthesis, mtFabH has attracted considerable attention as a good
anti-mycobacterial target.

xvii

In this study, we utilized important biochemical tools such as site directed
mutagenesis, mass spectrometry and X-ray crystallography to address some of the key
unanswered questions regarding the intricate workings of mtFabH. We solved the first
co-crystal structure of substrate C12CoA with mtFabH and further analyzed the substrate
specificity of this acylation step. This structure depicts the mode of acyl-CoA binding in
mtFabH channels; and its comparison with the parallel E.Coli-acetyl CoA structure
provides important similarities and differences in substrate binding in these two FabH
enzymes. It also posed an important question about the trajectory of long acyl chain CoA
into the deep and “seemingly closed” substrate binding pocket of mtFabH. By utilizing
disulfide-based inhibitors, we showed that large conformational changes are necessary to
facilitate ligand trafficking in mtFabH while the high catalytic turnover rate of the
enzyme is maintained. We also proposed the most likely location of the involved loop.
A much faster and less cumbersome assay for mtFabH was also developed and it
was utilized to characterize a series of inhibitors. This assay utilizes the commercially
available radioactive malonyl-CoA in lieu of malonyl-ACP, the physiological substrate,
and thus can serve as ACP independent assay for mtFabH.
These studies further our understanding of the biochemistry of mtFabH, which
along with the faster assay could be helpful in designing potent mtFabH inhibitors as
anti-tubercular agents in the future.
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1. Introduction

1.1 Tuberculosis: a global burden
Tuberculosis is one of the deadliest diseases of the present time: one third of the
world’s total population - approximately two billion people - is currently infected with it,
and it causes more deaths than any other single infectious disease.1 According to the
World Health Organization (WHO), about eight million people develop active TB every
year and close to two million die from it.2 It is estimated that by the end of year 2020,
nearly one billion new infections will be reported; of those, about 200 million people will
have active TB and about 70 million will die from it, if new and improved treatments are
not introduced.3,4
TB

is

caused

by

mycobacteria

of

‘tuberculosis

complex’

primarily

Mycobacterium tuberculosis, but also Mycobacterium bovis and Mycobacterium
africanum. This highly contagious disease is transmitted through the air by inhalation of
infective droplet nuclei spread by sneezing, coughing, talking or spitting, and it infects
lungs, brain, spinal cord, bones, and joints and various other organs. The rod shaped,
acid-fast TB bacillus invades the lungs through the air canal from where it may spread to
various other parts of the body through the blood stream, if left untreated. Development
of anti-tubercular drugs such as isoniazid, rifampicin, ethambutol and pyrazinamide led
to the near-eradication of TB two decades ago but recent emergence of HIV/AIDS and its
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synergy with TB has caused the resurgence of TB on a much larger scale than ever,
especially in developing countries (Figure 1). In 1993, the gravity of the problem led
WHO to declare TB as a global emergency in an attempt to heighten political and public
awareness. TB is the leading killer among HIV-infected persons, because they have
weakened immune systems, with quarter million TB deaths being HIV-related.

Figure 1: The estimated incidence rates of tuberculosis in different parts of the world in the year
2003. The data is reported by World Health Organization (WHO) and numbers are given per 100,000.

A further complicating factor that has resulted in the rise of TB is emergence of
new strains of M. tuberculosis which are resistant to one or more current anti-tubercular
drugs (Multi Drug Resistant TB or MDR-TB).5,6 According to a recent survey by WHO
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and its partners, MDR-TB is present in all of the 109 countries surveyed.1 Multiple
reasons have been associated with the development of this resistance by the TB bacillus,
including patient’s non-compliance with treatment, prescription of incorrect treatment,
unreliable drug supply, or inconsistent or incomplete treatment.7 The current revised TB
treatment recommended by World Health Organization (WHO) is a 6-8 month ‘short’
therapy with a frontline anti-tubercular drug cocktail consisting of isoniazid, rifampicin,
ethambutol, pyrazinamide and streptomycin specifically implemented by the DOTS
program (Directly Observed Treatment, Short course).1 Extensive research is underway
in many federal, academic and industrial laboratories to explore new targets and drugs to
fight this growing global problem.

1.2 Mycobacteria: the Fort Knox of bacteria
The exceptional pathogenicity and virulence of TB bacteria are largely associated
with its formidable cell wall,8-10 a very unique structural feature of the CornyebacteriumMycobacterium-Nocardium (CMN) branch of Actinomycetes order, to which M.
tuberculosis belongs. This unusual and highly hydrophobic mycobacterial cell wall is
composed of three main structural components: arabinogalactan, peptidoglycan and the
hallmark of mycobacteria, mycolic acid (Figure 2). These three components are
covalently linked (thus often referred to as mycolyl-Arabino-Galactan-Peptidoglycan
complex or mAGP) and provide the basic framework of the mycobacterial cell wall.11
Mycolic acids, in particular, are of special interest because of their unique chemical
structure and their highly lipophilic nature, which primarily regulates the permeability of

4

the mycobacterial cell wall.12,13 The importance of mycolic acid is evidenced by the fact
that it comprises 60 % of the weight of the cell wall.14

Figure 2: Schematic representation of the mycobacterial cell wall. A layer of peptidoglycan
encapsulates the plasma membrane and is covalently linked to mycolyl-arabinogalactan by an unusual
disaccharide phosphate bond. The mycolic acid chains are shown perpendicular to the plasma membrane
and the exposed portion is seen interacting with trehalose dimycolate, the extractable lipids of
mycobacterial cell wall.

Mycolic acids are high molecular weight α- alkyl β- hydroxy fatty acid (C50-C90)
that are found either covalently attached to the mycobacterial cell wall in the form of
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mAGP or non-covalently as in trehalose dimycolates, the so-called extractable lipids.
They form a thick, robust lipid layer on the mycobacterial cell wall and perform a myriad

Figure 3: Various types of mycolic acids found in M. tuberculosis. α-Mycolates are the most
abundant mycolic acid type (~57%) in M. tuberculosis and its mero chain contains two ciscyclopropanes. Methoxymycolates, the second most abundant class of mycolic acid in M. tuberculosis
(~32%), contain an a-methyl methyl-ether moiety in the distal position and a cis-cyclopropane or an
α-methyl trans-cyclopropane in the proximal position. Ketomycolates, which are less abundant
(~11%), contain an a-methyl ketone moiety in the distal position and proximal functionalities as in the
methoxy series. (Adopted from ref. 27)

of gate keeper functions such as protecting the bacteria from the toxic external
environments of the host immune system8,15,16 and commonly used antibiotics.17 The
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alkyl chains of mycolic acids are species-specific with the α-alkyl branch ranging from
22-26 carbons and the long meromycolic acid ranging from 50-63 carbons. M.
tuberculosis contains the longest alkyl branches in its genera with an α -branch up to 26
carbons and meromycolic acid arms up to 63 carbons. The meromycolic arm of mycolic
acids is further functionalized by a combination of unsaturation, cyclopropanation and
oxygenation (Figure 3). These are proposed to impart and regulate various important cell
wall properties of mycobacterium, such as fluidity and anchoring to the host cell surface
molecules, thereby defining its role in survival and pathogenesis.13,18,19 These unique
properties, conferred only by mycolic acids, make TB bacilli one of the toughest disease
opponents ever faced by mankind.

1.3 Mycolic Acid and Fatty Acid Biosynthesis
The backbone of mycolic acids, the shorter alpha branch and the longer
meromycolate alkyl chains, are synthesized by the ubiquitous and well-characterized
Fatty Acid Synthases (FAS). Fatty acid biosynthesis, an essential process in all
organisms, is catalyzed by two distinct systems, Type I in mammals and fungi20 and Type
II in plants and bacteria21 (Figure 4). The Type I FAS system is characterized by one (in
mammals) or two (in fungi and Corynebacterium ammoniagenes) polypeptide chains
containing multiple domains, which catalyze all of the different steps of the FAS cycle.
These polypeptides include the Acyl Carrier Protein (ACP), which ferries the growing
acyl chain from one domain to another. In the Type II system, each FAS reaction is
carried out by a discrete enzyme encoded by an individual gene.

7

Figure 4: The organization of fatty acid biosynthesis in Type I (a) and Type II FAS (b): (a) In
mammals, a single multifunctional polypeptide complex (existing as a dimer) performs fatty acid
biosynthesis and the growing acyl chain remains bound until chain elongation is complete. (b) In
bacteria, each of the FAS II reaction is performed by discrete proteins and the pathway
intermediates are ferried from one specific protein to the next as thioester derivatives of acyl carrier
protein (ACP). The figure in bracket (e.g. 2C) denotes the length of the carbon chain. (Adopted from
ref. 23)
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The intermediates in a Type II FAS are carried from one enzyme to another by a discrete
acyl carrier protein (ACP). The various reactions carried out by the Type I and Type II
FAS system are essentially the same in spite of their organizational differences.22,23 In
general, transfer of the acyl moiety from acyl coenzyme A (CoA) to the active site
cysteine of ketosynthase III (FabH), followed by condensation with malonyl-ACP to
form the β-ketoacyl-ACP product, is the reaction that initiates the FAS process. The
analogous ketosynthases, FabB and FabF, which take up acyl ACP in place of acyl-CoAs
as substrate, catalyze subsequent condensation reactions. Malonyl-ACP is derived from
the transfer of a malonyl group from malonyl-CoA to ACP catalyzed by the enzyme
malonyl-CoA: ACP transferase or FabD. After each condensation step, the growing βketoacyl product is converted into acyl-ACP by the sequential enzymatic action of βketoacyl-ACP reductase (FabG), β-hydroxyacyl ACP dehydrase (FabA or FabZ), and an
NADH-dependent enoyl ACP reductase (FabI) (Figure 5).
Mycobacteria are distinct from other bacteria because they possess both Type I
and Type II fatty acid biosynthesis systems.24,25 The type I FAS of mycobacteria is
responsible for the de novo production of the α- branch of the mycolic acid as well as the
meromycolate “primer” acyl chain that is further elongated by the type II FAS system. A
key regulatory enzyme termed mtFabH or ketoacyl-synthase III (KAS III) forms the
pivotal link between the last cycle of FAS I and the first cycle of FAS II systems in M.
tuberculosis.26,27 mtFabH preferentially catalyzes the condensation of C16/C24 acyl-CoA
(released from FAS I) and malonyl-ACP to form the corresponding β-ketoacyl-ACP
product, which is further taken up by the Type II FAS system of mycobacterium and
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Figure 5: The bacterial type II FAS pathway depicting the general reactions of fatty acid biosynthesis. The organization of Type I and
Type II FAS is different as shown in figure 4 but the nature of reactions carried out by both systems are essentially the same. First, Acetyl-CoA
(Ac-CoA) is carboxylated by heterotetrameric AccABCD to form malonyl-CoA which is then tranferred to ACP by enzyme FabD. Fatty Acid
Biosynthesis is catalyzed by iterated cycles of condensation (FabH, FabB, FabF), reduction (FabG), dehydration (FabA or FabZ) and reduction
(FabI or FabK) steps as shown above. (Adopted with modifications from ref.22)
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elongated to C24-C63 carbon meromycolates. Finally, these meromycolates are condensed
with the shorter (C23-C26) alpha alkyl chain from FAS I to form mature mycolic acids
(Figure 6).28
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Figure 6: Importance of mtFabH in fatty acid elongation and mycolic acid biosynthesis in M. tuberculosis. The fatty acids produced by the type
I synthase are removed from the complex by an unidentified transacylase yielding long-chain acyl-CoAs. These acyl-CoAs are used either for alpha
branch of mature mycolic acids or by mtFabH, which initiates a round of elongation by the type II Synthase that eventually produces the
meromycolate branch of mycolic acids. The shorter alpha branch from FAS I and the longer meromycolate from FAS II condense to form mature
mycolic acids, which are incorporated into the cell wall.
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1.4 Mycolate biosynthesis: the target of current anti-tubercular drugs
Mycolic acid, due to its incredible chemical structure and crucial role in
mycobacterial virulence and impenetrability, has always been a very important target in
anti-mycobacterial drug design. Many of the currently used and highly effective antitubercular drugs inhibit fatty acid biosynthesis involved in synthesis of alkyl chains of
mature mycolates, thus validating the suitability of mycolate and fatty acid biosyntheses
as excellent drug targets.29 Important anti-tubercular drugs, which act by inhibiting one or
more components of FAS in TB bacteria, are shown in Figure 7 and clinically relevant
drugs are discussed in detail below.

1.4.1 Isoniazid (INH)
Isoniazid (INH or isonicotinic acid hydrazide) was first discovered as an antitubercular drug in 1952 and since then it has been used clinically as a frontline drug of
choice for treatment of tuberculosis. Both M. tuberculosis and M. bovis were found
susceptible to INH with a MIC range of 0.02 –0.2 µg/ml. INH acts as a bactericidal agent
by causing bacterial lysis within twenty four hours of its treatment. Although the drug
had been known to block mycolic acid biosynthesis,30-33 the precise enzymatic target and
thus the mechanism of action of INH remained elusive for over forty years. In 1994, for
the first time, Banerjee et al34 traced the target of INH to be a product of the structural
gene inhA, which was later found to code for an NADH-dependent FAS II enoyl-ACP
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Figure 7: Structures of various anti-mycobacterial agents: Anti-tubercular agents,
which inhibit one or more components of mycolic acid biosynthetic pathway.

14

reductase in M . tuberculosis termed InhA (equivalent to FabI of E. coli). However, with
the finding that another fatty acid enzyme – the condensation enzyme KasA (an E. coli
ketoacyl-synthase I equivalent) of type II FAS in M. tuberculosis – is also bound to a
INH-ACPM complex and therefore a potential target of INH,35 it is currently debated
whether INH may have more than one target in M. tuberculosis. Moreover, a non-FAS
enzyme, dihydrofolate reductase (DHFR) of nucleic acid biosynthesis, has also recently
been proven to be inactivated by INH and is thus also claimed to be a physiological target
of INH.36 Probably the success of INH all these years was, in fact, due to its inhibition of
more than one enzyme, which has made it difficult for bacteria to develop resistance
against it.

1.4.1.1 Isoniazid: mechanism of action and resistance development
INH is shown to be a prodrug in M. tuberculosis: it requires activation by an
oxidizing enzyme, KatG peroxidase, to be converted into its active intermediate as shown
in Figure 8. It is proposed that INH is first oxidized by KatG peroxidase to produce the
highly reactive intermediate 1 or 2 (isonicotinic acid anion or a free radical), which then
reacts respectively with either NAD+ or NAD˙ (in the absence of KatG) to form the INHNAD adduct. This final electrophilic adduct is shown to bind and inhibit InhA at a
nanomolar range37 and is also most likely the species involved in inhibition of KasA. The
idea that the activated adduct formed between INH and NAD+ could possibly attack any
of the cellular NADH dependent enzymes has, at least theoretically, fostered the belief
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1

2

Figure 8: Proposed pathway for formation of the isonicotinic acyl-NADH inhibitor of InhA. Two
possible scenarios are shown, in which an activated form of isoniazid (isonicotinic acyl anion or radical)
covalently attaches to a form of NADH (NAD1 or NAD. radical) within the active site of InhA, while
retaining a tetrahedral carbon at position four of the nicotinamide ring. (Adopted from ref. 37)
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that more than one NADH-dependent enzyme could be a target for INH. Although INH
resistance has been shown to correlate to mutation or deletion in the KatG gene in at least
50% of clinically resistant M. tuberculosis strains,38 analysis of all available resistant
strains suggests potential involvement of at least four other genes, including KasA and
inhA.6 The number of total enzymes involved in INH inhibition and the extent of
inhibition is currently debatable, but all evidence so far inarguably maintains that InhA is
the major target of INH.

1.4.2 Pyrazinamide (PZA)
Pyrazinamide (PZA) was discovered in 1952 in an attempt to find more potent
analogs of nicotinamide, a compound found to have weak anti-tubercular activity. But
unlike isoniazid, pyrazinamide was not used extensively in treatment of TB until the mid1980s. The later finding that PZA exerts strong synergistic and accelerating effects on
other anti-tubercular drugs has resulted in its current recommendation in every
combination therapy for the treatment of the disease. The MIC of PZA varies from 8-60
µg/ml depending on the assay method and media employed.39 It is found to be active
against M. tuberculosis, but not against M. bovis and other rapidly-growing
mycobacterial species.
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1.4.2.1 Pyrazinamide: Mechanism of action and resistance development
Like INH, pyrazinamide is also a pro-drug that requires amide hydrolysis by
mycobacterial pyrazinamidase (a nicotinamidase) to convert to pyrazinoic acid, its active
form.40 This mechanism of activation is evidenced by the fact that pyrazinoic acid and its
various analogs were found to have at least equivalent or better activity against clinically
resistant strains of M. tuberculosis and naturally resistant strains of M. bovis, which lacks
pyrazinamidase activity.41,42 After activation, PZA is found to exert its anti-tubercular
effect by inhibiting the Type I FAS multifunctional enzyme in M. tuberculosis with no
effect on Type II enzymes. PZA inhibits [C14] acetate incorporation into C16-C24/C26 fatty
acid whereas [C14] palmitate incorporation into mycolic acid is unaffected, strongly
suggesting that type I FAS is indeed the target; interestingly, however, PZA does not
block mycolic acid synthesis, which raises important doubts about its mode of action.
Resistance against PZA is shown to be related to loss of pyrazinamidase activity in M.
tuberculosis.

1.4.3 Miscellaneous inhibitors
Apart from the WHO-recommended frontline anti-tubercular drugs INH and PZA,
several second-line drugs including ethionamide, thioacetazone, and thiocarlide (isoxyl)
have been shown to exert anti-tubercular activity via the proposed inhibition of one or
more components of mycolic acid biosynthesis (see Figure 7). Also well known
antibacterials like triclosan and cerulenin are also proven to exert their inhibitory effect
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by acting on one or more enzymes of fatty acid biosynthesis in bacteria. Thus, there is
ample evidence available that mycolic acid biosynthesis is an excellent drug target.
A relatively newer addition to the anti-tubercular drug list is the compound PA824 which also shows significant activity against the clinically resistant TB strains.43,44
PA-824, a 3-substituted nitroimidazopyran, was initially discovered for cancer treatment
and has been shown to possess highly specific activity towards M. tuberculosis complex
by possibly inhibiting mycolic acid biosynthesis and protein synthesis. It is now widely
touted as the next potential TB drug, as it has shown great promise in pre-clinical trials.
PA-284 is also proposed to be a pro-drug based on the available data, but its exact nature
of inhibition and physiological target are still unclear.45
Thiolactomycin (TLM), a unique thiolactone antibiotic produced as a secondary
metabolite of the soil fungi Nocardia sp., has been shown to have potent anti-microbial
activity against several pathogens46-48 including the saprophytic strain Mycobacterium
smegmatis mc2155 and the virulent strain M. tuberculosis Erdman.49 It blocks the Type II
fatty acid synthase system in M. tuberculosis by inhibiting two key FAS condensing
enzymes, ketoacyl synthase I (KasA) and III, both in-vitro and in-vivo; this ultimately
leads to blockage of mycolic acid biosynthesis and cell death.49,50 These findings have
encouraged the synthesis of a series of TLM analogs, many of which were found to be
more potent than their parent compound TLM.51-54
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1.5 mtFabH as an emerging anti-tubercular target
Over the last decade, the resurgence of TB has created the necessity to find novel
anti-tubercular targets and drugs. Key anti-tubercular drugs including frontline drugs like
isoniazid (INH) and pyrazinamide (PZA) have been found to exert inhibitory action by
blocking the synthesis of fatty acid, which corroborates the validity of FAS enzymes as

Figure 9: Sequence alignment of FabH from E. coli, S. glaucescens, and M. tuberculosis. Positions of
inserts in the latter two sequences are based on comparison of tertiary structures, not on sequence
similarity, and are numbered with extensions to the residue number just preceding the insert. Boxed
residues are a-helix present in mtFabH and missing in ecFabH and the putative specificity determinant at
residue 87 (see figure 11 for detail). Asterisks denote active-site residues. (Adopted from ref.27)
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targets for the development of novel anti-tubercular drugs. What makes mtFabH unique
from other FAS enzymes is its capacity to link the two indispensable FAS systems; the
enzyme thus plays a key role in mycolic acid biosynthesis in M. tuberculosis. Moreover,
the absence of a human homologue of FabH has helped it garner significant interest as an
anti-tubercular target and considerable effort is being directed at understanding its
detailed mechanism by researchers around the globe.

Figure 10: Comparison of backbone folds for ecFabH (blue) and mtFabH (bronze) dimers. The
insert at position 202 in mtFabH relative to ecFabH and the contiguous α-helix (cylinder) immediately
preceding this insertion in mtFabH are colored red. The arrow indicates the non-crystallographic 2-fold
axis defining the functional mtFabH dimer. (Adopted from ref. 27)
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mtFabH is one of three condensing enzymes found in the type II FAS system of M.
tuberculosis.
This approximately 70 kD homodimer is encoded by the open reading frame
Rv0533c (fabH ~ 1005 bp) of M. tuberculosis (H37Rv) chromosomal DNA and found to
have high sequence similarity to its E. coli (ecFabH) and S. glaucescens (sgFabH)
homologues (Figure 9).

26,55,56

The closely related FabH enzymes, mtFabH and ecFabH,

are seen to have the same core structure (figure 10) with the same characteristic buried
Cys-His-Asn catalytic triad and the coenzyme-A/ACP binding channel; but unlike
ecFabH, mtFabH takes up longer acyl-CoAs (C6 – C20) (Table 1), which is consistent
Acyl-CoA

mtFabH (with ecACP)

mtFabH (with ACPM)
Enzymatic activity (pmoles/min/ug)

Acetyl CoA
Butyryl CoA
Isovaleryl CoA
Hexanoyl CoA
Octanoyl CoA
Decanoyl CoA
Lauroyl-CoA
Myristoyl CoA
Palmitoyl CoA
Stearoyl CoA
Arachidoyl CoA

(2:0)
(4:0)
(5:0)
(6:0)
(8:0)
(10:0)
(12:0)
(14:0)
(16:0)
(18:0)
(20:0)

n.d.
n.d.
n.d.
0.39 +/- 0.07
5.98 +/- 0.19
6.34 +/- 0.49
8.01 +/- 1.07
2.24 +/- 0.10
1.33 +/- 0.10
0.60 +/- 0.10
0.06 +/- 0.02

n.d.
n.d.
n.d.
1.74 +/- 0.07
5.49 +/- 0.93
6.16 +/- 0.24
7.24 +/- 0.18
9.46 +/- 0.41
9.27 +/- 0.56
10.39 +/- 0.51
9.02 +/- 0.0.27

ecFabH
(* 103)

50.5 +/- 4.5
5.30 +/- 0.20
3.80 +/- 0.02
3.40 +/- 0.60
n.d.
n.d.
3.30 +/- 0.20
n.d.
n.d.
n.d.
n.d.

Table 1: Substrate specificity of mtFabH (with homologous and heterologous ACP) and ecFabH
towards various acyl-CoAs. For mtFabH specificity, the β -hydroxyacyl-ACP (either ec-ACP or mtACP)
product formed is reduced with sodium NaBH4 and extracted with toluene and counted with liquid
scintillation counter. For ecFabH specificity, enzyme activity was determined using 50 mM acyl-CoA, 7
mM malonyl- ACP, 100 mM NADPH, 1.5 mg S. pneumoniae FabG and 5 ng of E. coli FabH. The FabHFabG spectrophotometric-coupled assay was used to determine the substrate specificity of E. coli FabH for
various acyl-CoA primers. In the coupled assay malonyl-ACP and acyl-CoA are condensed by E. coli FabH
to yield β-ketoacyl-ACP, which is a substrate of S. pneumoniae FabG. FabG catalyzes the reduction of βketoacyl-ACP to β -hydroxyacyl-ACP and the concomitant oxidation of NADPH to NADP+, a coupled
reaction which was be monitored spectrophotometrically at 340 nm. (n.d.- Not determined)
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Figure 11: Modeled position of the myristoyl group in binding channel 2 showing the position of
residue 87B, which is a threonine in mtFabH (blue) and a phenylalanine in ecFabH (green). Residue
87 is proposed to contribute to fatty acid chain length specificity for these two enzymes. (Adopted from ref.
27)

Figure 12: Magnified view of the distal end of the myristoyl-binding site in mtFabH at the junction
of the inserts of each monomer. The insert and preceding α-helix are shown in red, and the modeled
myristoyl group (Ma and Mb in each subunit) is shown in lavender. Note the space in the FabH binding
site for two more carbons on the end of myristoyl. (Adopted from ref. 27)
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with its role of extending the type I FAS acyl-CoA products. The preference for a longer
acyl chain in mtFabH is proposed to arise from the presence of permissive Thr87B
(compared to Phe87B in E. coli) which opens up the putative acyl channel in mtFabH to
accommodate the longer acyl group (Figure 12). In the homologous sgFabH, the presence
of identical Thr87B (Figure 9) and the relaxed substrate specificity relative to ecFabH fully
support this hypothesis.55 The acyl chain length specificity for mtFabH was proposed to
be limited to a maximum of C16CoA due to the positioning of a steric cap produced by
the alpha helix at positions 194-202 on the acyl channel (see Figures 9 and 13). This
maximal chain length effect was later seen to be the result of the heterologous ACP
(ecACP) used in the study, as the utilization of homologous ACPM resulted in efficient
condensation of physiologically relevant substrates (up to C20-CoA) (Figure 11).57

1.5.1 Mechanism of the mtFabH reaction
mtFabH is proposed to utilize C16 - C20 acyl-CoAs produced by the Type I FAS
system and condenses them with malonyl-ACPM by a multi-step ‘ping-pong’ mechanism
to form the corresponding two-carbon-longer β-ketoacyl-ACP product (Figure 14). The
first step is the formation of an acyl-mtFabH intermediate by the attack of Cys112
thiolate of mtFabH on the carbonyl carbon of the first substrate acyl-CoA
(transacylation). In the subsequent step, CoA is released and the second substrate
malonyl-ACP binds in the same pocket and decarboxylates to produce a carbanion. This
carbanion then attacks the electrophilic acyl carbonyl of acyl-mtFabH to form the final βketoacyl-ACP product (condensation) which is released to recycle the free mtFabH. This
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long-chain β-ketoacyl-CoA product is then processed by the Type II FAS in M.
tuberculosis to form the mature meromycolate chains.

Figure 13: Mechanism for the mtFabH catalyzed initiation of fatty acid biosynthesis. The acylCoA depicted here is lauroyl CoA (12:0) which is elongated by 2 carbons provided by malonyl
moiety attached to ACPM.
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1.6 Thesis objectives
The discovery of mtFabH and its proposed pivotal role in M. tuberculosis functioning
has instigated significant interest in this enzyme, and the recent unraveling of the mtFabH
structure has provided important preliminary structure-function insights into this enzyme.
Some very crucial and relevant questions, however, still remain unanswered. Also, the
lack of an easier and more efficient assay format to test potential inhibitors for this
enzyme constitutes a serious roadblock to development of a specific inhibitor. Thus, we
directed our efforts towards investigating different mechanistic aspects of the enzyme
using various ligands; the long-term goal and future prospects were to discover novel,
potent, and selective inhibitors of mtFabH. The specific aims in these regards were as
follows:

1. Development of an easier and relatively faster assay format to aid in discovery of
potential inhibitors of mtFabH. The previous mtFabH assays require cumbersome
washing steps, expensive scintillation proximity beads or the tedious preparation of
biotinylated acyl carrier proteins. These factors are an impediment to the faster
screening of potential inhibitors and thus a more efficient assay format should
expedite their discovery. Here, we describe a much faster and less cumbersome
mtFabH assay that directly utilizes commercially available substrate malonyl-CoA (in
place of Malonyl-ACP) and thus overcomes the above mentioned disadvantages
associated with previous methods.
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2. Evaluation of the acyl binding pocket of mtFabH: The unique acyl binding pocket
of mtFabH has been speculated but not proven to be responsible for its different
substrate specificity compared to homologous ecFabH. Thus, we co-crystallized the
Michaelis Complex between mtFabH and the first substrate acyl-CoA to evaluate its
binding mode in the putative channels and to further compare it with the available
ecFabH-acetyl-CoA co-crystal structure. This structural comparison should aid in
design and development of effective inhibitors for these enzymes.
3. Probing the reactivity and substrate specificity of both monomers of the
mtFabH: The slower acylation rate relative to overall rate of condensation reaction
for mtFabH reported by Besra et al. poses a question-mark on proposed functional
equivalency between the two subunits of mtFabH. Also it further points towards a
more involved (complex) role of cognate ACPM in the overall reaction. Here, we
have utilized a mixture of C6-C20 CoAs and decyl-CoA disulfide to investigate the
reactivity and substrate specificity of individual monomers of the mtFabH dimer. The
results indicate a role of ACPM in priming and/or offloading of 3-ketoacyl ACPM
product.
4. Separate entrance and exit portals for ligand traffic in mtFabH: The unique
substrate specificity of mtFabH and other downstream M. tuberculosis FAS II
enzymes such as InhA and MabA for longer acyl-CoAs and ACPs poses an
interesting question of large ligand trafficking in these enzymes. We utilized a series
of disulfide-based inhibitors and a mtFabH mutant (whose pantotheinate binding
channel is blocked by A246F mutation) to investigate the entry/exit of large ligands
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to/from the deep and seemingly restricted mtFabH binding sites. We utilized mass
spectrometry and x-ray crystallographic studies to provide the experimental support
for an alternate route/conformation for ligand trafficking in mtFabH. This is a first for
the FabH class of enzymes, especially for mtFabH, and could be a key to
understanding the molecular interactions preceding the formation of the first mtFabHligand complex and also following the product formation.
5. Analysis of potential new mtFabH inhibitors: A series of FabH inhibitors have
been identified for E. Coli and Plasmodium Falciparum FabH by techniques such as
in-silico screening and chemical database searches. These inhibitors were evaluated
for their activity against mtFabH and attempts were made to analyze the basis of
inhibition against FabH class of enzymes.
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2. Development of Mycobacterium tuberculosis β-Ketoacyl-Acyl Carrier

Protein Synthase III (mtFabH) assay

2.1 Summary
The enzyme β-ketoacyl-ACP synthase (KAS III or FabH) is the key enzyme that
initiates fatty acid biosynthesis in a type II dissociated FAS. It catalyzes the condensation
of acyl-CoA and malonyl-ACP to form a β-ketoacyl-ACP product that is further
processed to form mature fatty acids that are involved in various essential cellular
processes like phospholipid biosynthesis, cell wall formation, etc. Herein described is a
new assay for the Mycobacterium tuberculosis FabH (mtFabH) enzyme involved in a key
initiation step in the synthesis of mycolic acids, which are an integral component of the
cell wall. The assay eliminates the need for the cumbersome washing steps, specialty
scintillation proximity assay beads, and the preparation of acyl carrier proteins, required
in other assay formats. This discontinuous assay involves the reduction of radiolabled
long chain β-ketoacyl-CoA product to its di-hydroxy derivative, which partitions into a
non-polar phase for quantitation, while the reduced radiolabeled substrate derivative
remains in the aqueous phase.
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2.2 Introduction
The most commonly used and established method to assay FabH involves the use
of radioactive acyl-CoA and malonyl-ACP to form a radioactive β-ketoacyl-ACP
product. This radioactive protein (ACP) product can be precipitated with acid, washed
and counted, while the radioactive substrate stays in the aqueous phase. The accuracy of
the assay requires extensive time–consuming washing steps. Nonetheless, this general
approach has been used to assay FabH from various pathogenic microorganisms such as
E. coli, E. faecalis, H. influenzae, S. pyogenes and S. aureus.58,59 Unfortunately, this
method can’t be used to assay mtFabH because the long chain acyl-CoA substrates
utilized by mtFabH have poor water solubility and are not readily resolved from the βketoacyl-ACP product by the acid precipitation and extensive washing steps. Other assay
formats such as a Scintillation Proximity Assay (SPA)27 and a filter disk assay26 have
been described and can successfully be used for mtFabH. However, these assays involve
either tedious preparation of a biotinylated malonyl-ACP substrate (SPA) or numerous
washing steps (filter disk assay). The assay described here is a faster and more cost
efficient for mtFabH, and eliminates the requirement of prior preparation of ACP
substrates. Each individual step of the assay format is described in detail with special
notes explaining the key steps. Furthermore, the advantages and disadvantages of this
new assay method are discussed.
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2.3 Experimental procedure:
2.3.1 Materials:
The following reagents and conditions were used in the assay. The stock and working
concentrations are indicated where required.
1. Lauroyl-CoA or other long chain acyl-CoA (Sigma) – the stock solution of 100mM or
10 mM were made in aqueous hydrochloric acid, pH 3.5, then diluted to 100uM
working concentrations, aliquoted into appropriate working volumes and stored at –
80 oC.
Note: As acyl-CoA substrates are known to be unstable at neutral and higher pH, the
solutions were made in acidic pH (aqueous hydrochloric acid solutions at pH 3.5) and
stored in aliquots at –80 oC in working volumes (avoiding the need to repeatedly thaw
and refreeze the solutions and the associated increased degradation).
2. Radioactive [2-14C] Malonyl-CoA (American Radiolabeled Chemicals Inc.)(Stock
concentration 1.8 mM; specific activity, 55mCi/mmol) diluted approximately 7.2
times in aqueous hydrochloric acid solution (pH 3.5); the resulting 250 µM solution
was aliquoted into appropriate working volumes and stored at – 80 oC.
Note: The purity of the commercially available radioactive malonyl-CoA is a very
important factor in this particular assay. Radioactive malonyl-CoA is prepared by the
reaction of monothiophenylmalonate [malonyl-2-14C] and coenzyme A and the [214

C] malonyl-CoA product is purified by column chromatography. The radioactive
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reactant is relatively non-polar, and if present in the [2-14C] malonyl-CoA sample, can
lead to a high background during the assay and a substantially reduced signal to noise
ratio. The manufacturer’s technical data sheet states that under these conditions the
rate of decomposition is approximately 2% over the first six months.
3. The over-expression of mtFabH enzyme in E coli and its purification has been
described previously.27
4. Sodium borohydride, toluene and tetrahydrofuran (THF) were from Fisher Scientific.
5. Double distilled (DD) water (Sigma) for preparing buffers and reagents.
Note: Divalent cations like Mg2+, Mn2+ catalyze the decomposition of sodium
borohydride (NaBH4) preventing effective reduction of the β-ketoacyl-CoA product.
Thus distilled water free of divalent ions was used in both the working assay and the
preparation of the reducing reagent solution.60
6. Potassium chloride powder, dibasic potassium phosphate powder (required for
making reducing reagent) was ordered from Sigma.
7. Screw cap microcentrifuge tubes (VWR).
Note: Sodium borohydride produces significant effervescence when mixed with
aqueous solutions. There is thus a potential for loss of the radioactive material from
the vial at this point. A screw cap micro centrifuge tube should be used and tightened
carefully before shaking the sample.
8. EcoScint A scintillation cocktail (National Diagnostics).
9. High-Density Polyethylene (HDPE) Liquid Scintillation Vials (Wheaton Science).
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2.3.2. Method:
The reaction was carried out in 20 µl total volume. This low volume using a
minimum of the commercial radioactive malonyl-CoA sample with an unchanged
specific activity balanced a high signal to noise ratio with a low cost. A larger volume
assay would either require additional radioactive malonyl-CoA (increased cost) or
addition of unlabeled malonyl-CoA (decreasing the specific activity and signal to noise
ratio). The concentrations of various components in a typical assay are shown in table 2.
These volumes permitted determination of an IC50 value for a mtFabH inhibitor, but can
be modified to perform routine enzymatic studies by replacement with an additional 2 µl
of buffer.

Component
Lauroyl-CoA
Malonyl-CoA
Inhibitor
mtFabH
Sodium phos., pH 7.0
Total volume

Stock Conc.
100 µM
250 µM
10 X
100 mM

Volume used
2.5 µl
1 µl
2 µl
2 µl
12.5 µl

Final conc./ amount
12.5 µM
12.5 µM
1X
0.2 µg
72 mM

20 µl

Table 2: List of various components of a typical mtFabH assay.

Steps:
1. The desired number of lauroyl-CoA, malonyl-CoA and mtFabH aliquots were thawed
and kept at 4 0C.
2. In a screw cap microcentrifuge tube, 2.5 µl of 100 µM lauroyl-CoA solution (final
concentration 12.5 µM lauroyl-CoA), 1 µl of the 250 µM [2-14C] malonyl-CoA
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solution (approx. 31,000 counts, final concentration 12.5 µM) and 2 µl of 10X
inhibitor concentration (for inhibitor IC50 studies) were added. Then 0.1M sodium
phosphate buffer, pH 7.0 was added to make up the volume to 18 µl.
Note: The solvents used to deliver inhibitors have a predictable inhibitory effect on
the activity of mtFabH. The effect of various concentrations of dimethylsulfoxide
(DMSO) and methanol (MeOH) is shown in figure 14. These figures indicate that the
concentrations of solvent should ideally be at or below 1 % in the final assay volume.

120
DMSO

% mtFabH Activity

100

MeOH

80
60
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20
0
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0.1

1
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Figure 14: Effect of solvent concentrations (DMSO and methanol) on mtFabH activity.
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3. The reaction was initiated by addition of 2 µl of mtFabH 0.2 – 0.4 µg) solution in 0.1
M sodium phosphate buffer, pH 7.0. Cap the microcentrifuge tube and kept at 37 0C
for a designated time (typically 30-90 minutes). Under these assay conditions a linear
reaction rate was observed for over a 2-hour assay period. (Figure 15).
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Figure 15: Linearity of mtFabH activity with time. Enzyme is incubated with substrates at 37 oC
for the specified time and product formation quantitiated as described above.

4. The reducing reagent was generated by adding 5 mg of NaBH4 to 1 ml of a 70% 100
mM K2HPO4, 100mM KCl, 30% THF solution. This solution was prepared fresh, and
kept on ice until used.
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Note: The reducing solution consisted of 100 mM K2HPO4, 100mM KCl, 30% THF
with sodium borohydride as the reducing agent. THF decreases the time required to
quantitatively reduce the acyl thioesters (from 2 h to 10 min).60 The buffer can be
stored at room temperature and NaBH4 should be added just before use. This
reduction solution can be used for up to 2 hr if kept on ice, but potentially can lead to
a loss of consistency in the assay results.
5. A 0.5 ml of this reducing solution was added to the assay mixture; the vials were
capped and shaken vigorously. Incubate the mixture at 37 0C degree for 15 minutes.
Note: Reduction of long chain acyl-CoA is quantitative within 10 min. If inconsistent
results are obtained the reduction reaction can be carried out for a longer time.
6. Then 500 µl toluene was added to the mixture, the solution was mixed vigorously and
then allowed to separate at room temperature.
7. 320 µl of the upper phase (toluene) solvent was removed and combined with
approximately 3 ml of a toluene or xylene based scintillation liquid
8. The radioactivity of the toluene extract was determined with a Scintillation Counter
and the actual radioactivity in non-aqueous phase was calculated by doubling the
observed radioactivity.
Note: The volume of toluene solution increases to about 640 µl due to partitioning of
THF into toluene.
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Figure 16: Schematic of mtFabH assay. The principle of separation of radioactive substrate and
product is described in section 1.2. Radioactive center is shown by asterisk *. R’ can be either CoA or
ACP.
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2.4 Results and Discussion:
The commonly used assays for FabH enzymes (TCA precipitation and other assay
formats) are very time consuming and tedious to perform. The radioactive long chain acyl
substrate processed by mtFabH is very difficult to separate from the radioactive product
by the conventional washing step used in these assays. Recently, Brown et al57 have
developed an alternative assay method for mtFabH based on an assay used originally by
Garwin et al

61

for related FabF/FabB enzymes. This assay (Figure 16) involves the

reduction of the assay mixture after reaction completion to produce radioactive substrate
and product derivatives, which differ from each other in polarity. This difference permits
simple separation of the two and quantitation of the radioactive product. The assay uses
FabD to produce radioactive 2-14C malonyl-ACP in-situ from holo-ACP and malonylCoA. The mtFabH catalyzes a decarboxylative condensation of this malonyl-ACP with
the long chain acyl-CoA substrate ranging from hexanoyl CoA to arachidonyl CoA (C6 –
C20), (see Table 3) to form a long chain β-ketoacyl-ACP. Reduction of this product by
NaBH4 gives the corresponding radioactive long chain alkyl-1, 3-diol product with a 14C
label at C2. This product derivative can be partitioned into non-aqueous phase whereas
the radioactive propane-1, 3-diol obtained by reduction of the radioactive malonyl
thioesters stays in an aqueous phase. We have further simplified this by using malonylCoA directly as a substrate, instead of malonyl-ACP (see figure 16).
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mtFabH Specific Activity ( nMoles/min/mg)
Acyl-CoA primer chain length

ec-Malonyl-ACP (*)

mt-Malonyl-ACP (*)

Malonyl-CoA (#)

C6

0.39+/-0.07

1.74+/- 0.28

0.38+/- 0.064

C8

5.98+/- 0.19

5.49+/-0.93

0.69+/- 0.18

C10

6.34+/- 0.49

6.16+/- 0.24

0.758+/- 0.095

C12

8.01+/- 1.07

7.24+/- 0.18

1.77+/-0.041

C14

2.24+/-0.10

9.46+/- 0.41

0.3528+/- 0.0269

C16

1.33+/- 0.10

9.27+/- 0.56

0.128+/- 0.086

C18

0.60+/- 0.10

10.39+/- 0.51

0.036+/- 0.0009

C20

0.06+/- 0.02

9.02+/- 0.27

0.155+/- 0.0133

Table 3: Effect of ACP on acyl group specificity of mtFabH. Total condensation activity of mtFabH is
determined using ec-malonyl-ACP, mt-malonyl-ACP or malonyl-CoA and a range of different acyl-CoA
substrates. (* - Data adopted from reference 57, # - data for the assay described herein).

A slower reaction rate for mtFabH is observed when malonyl-CoA was used in
place of a malonyl-ACP substrate (Table 3). Dodecanoyl CoA is the preferred substrate
for assays using either malonyl-CoA or ec malonyl-ACP (generated from the Escherichia
coli ACP). With this acyl-CoA substrate the reaction rate is found to be about 4-fold
slower with malonyl-CoA than with ec-malonyl-ACP or malonyl-ACPM (generated from
the M. tuberculosis ACP). Catalysis with longer chain acyl-CoA substrates by the
mtFabH is markedly reduced using either ec-malonyl-ACP or malonyl-CoA, but not
malonyl-ACPM. One advantage of this modified assay is that all the substrates are
commercially available. There is no need to obtain a purified ACP, or convert it to either
the corresponding malonyl-ACP or biotinylated-malonyl-ACP, leading to significant
savings in both time and cost. The direct utilization of radioactive malonyl-CoA in the
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assay also maximizes the use of this substrate for the assay, avoiding the inevitable losses
associated with conversion to malonyl-ACP. The assay also uses lower concentrations of
malonyl-CoA (12.5 µM versus the 50 µM) typically used in other formats, both
decreasing the amount of material and potentially increasing the range of the assay to
include both poor and good competitive inhibitors. A final advantage of this new assay
format is an excellent 60:1 signal to noise ratio (the scintillation proximity assay27 is
approximately 10:1).

2.5 Conclusion:
In conclusion, the assay described herein is a much faster and less cumbersome
way to screen the potential inhibitors of mtFabH enzyme. Furthermore, the assay doesn’t
use ACP and thus can serve as an “ACP independent assay” for mtFabH enzyme. This
particular aspect can be utilized to investigate the role of various types of ACP substrates
for example- cognate vs non-cognate ACP. This assay is used to evaluate a series of
novel mtFabH inhibitors in later chapter (6) of this dissertation.
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3. Crystal structure of a substrate complex of Mycobacterium
tuberculosis β-Ketoacyl-Acyl Carrier Synthase III (mtFabH) with
Lauroyl-Coenzyme A

3.1 Summary
β-ketoacyl-acyl carrier protein synthase III (FabH) catalyzes a two step reaction
that initiates the pathway of fatty acid biosynthesis in plants and bacteria. In
Mycobacterium tuberculosis, FabH catalyzes extension of lauroyl, myristoyl and
palmitoyl groups from which cell wall mycolic acids of the bacterium are formed. The
first step of the reaction is an acyl group transfer from acyl-coenzyme A to the active-site
cysteine of the enzyme; the second step is acyl chain extension by two carbon atoms
through Claisen condensation with malonyl-acyl carrier protein. The crystal structure of a
type II dissociated M. tuberculosis FabH, which catalyzes extension of lauroyl, myristoyl
and palmitoyl groups, has been determined before. In this study, we describe the first
long-chain Michaelis substrate complex of a FabH, that of lauroyl-coenzyme A with a
catalytically disabled Cys→Ala mutant of M. tuberculosis FabH. An elongated channel
extending from the mutated active-site cysteine defines the acyl group binding locus that
confers unique acyl substrate specificity on M. tuberculosis FabH. CoA lies in a second
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channel, bound primarily through interactions of its nucleotide group at the enzyme
surface. The apparent weak association of CoA in this complex may play a role in the
binding and dissociation of long chain acyl-CoA substrates and products and poses
questions pertinent to the mechanism of this enzyme.

3.2 Introduction
The crystal structure of the homodimeric type II mtFabH was found to be very
similar in conformation to the other determined FabH structures,62,63 which adopt the
thiolase fold. The thiolase fold defines a growing family of enzymes that includes yeast
peroxisomal 3-ketoacyl-CoA thiolase,64 β-ketoacyl-acyl carrier protein synthases I
(FabB)65 and II (FabF),66,67 two plant type III polyketide synthases68,69 and one FabH
homologue from a type II bacterial polyketide synthase gene cluster.70 In contrast to the
Escherichia coli FabH structures, the mtFabH structure has a long channel extending
from its active-site Cys112, which has been tentatively identified as a long-chain acyl
group binding channel. This channel could accommodate an acyl chain of 12–16 carbon
atoms, consistent with the specificity of mtFabH observed in solution reactions.26,27 A
second channel, also extending from the active-site cysteine, corresponds to the CoA
binding channel identified in the E. coli FabH crystal structures. However, in the
unliganded mtFabH crystal structure, this second channel was occupied by electron
density that could be accurately modeled as a lauric acid, whose presence we ascribed to
adventitious binding during expression and purification of the recombinant mtFabH.
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To test our identification of these putative substrate binding channels and to
determine the binding mode of the physiologically relevant longer chain acyl-CoA to
mtFabH, we have determined the crystal structure of a substrate complex of lauroyl-CoA
with a catalytically inactive C112A mutant of this FabH. This complex represents the
presumed Michaelis complex of the reaction, which precedes acylation of the active-site
Cys112 and release of the CoA cofactor. Replacement of the active-site Cys112 of FabH
by alanine removes the enzyme acyl acceptor residue, thereby preventing the initial
transacylation and capturing the Michaelis complex.

3.3 Experimental Procedures
3.3.1 Materials
All general chemical supplies not listed below were ordered from standard
companies and were reagent grade or better. The source of specific supplies were as
follows: BL21DE codon plus cells and pET-15b plasmid for cloning were bought from
Novagen, QuikchangeTM XL site-directed mutagenesis kit was from Stratagene, HiTrap
TM

Chelating and Desalting columns used for protein procedures were from GE

Biosciences (formerly Amersham Biosciences), 50 kDa cutoff Microcon and Centricon
filters used were from Fisher scientific, crystal screen kits 1 and 2 and other
crystallization supplies were from Hampton research, primers were ordered from
Integrated DNA Technology and the QiaPrep MiniprepTM kit for DNA extraction was
from Qiagen.
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3.3.2 Construction of mtFabH mutants
The C112S and C112A mutations were made on the open reading frame Rv0533c
(mtFabH), which was cloned into the expression vector pET-15b as described.27 Mutants
were made according to the protocol provided for the Stratagene Quickchange XL sitedirected mutagenesis kit and primers designed to substitute serine and alanine for
Cys112. Primers used for introducing point mutations were, for the C112S mutant:
forward 5′-GAT CTT TCG GCG GGG AGC GCC GGA TTC GGA TAT G-3′, reverse 5′
-CAT ATC CGA ATC CGG CGC TCC CCG CCG AAA GAT C-3′, and for the C112A
mutant: forward 5′-GAT CTT TCG GCG GGG GCC GCC GGA TTC GGA TAT G-3′
and reverse 5′-CAT ATC CGA ATC CGG CGG CCC CCG CCG AAA GAT C-3′.
Mutations were confirmed by sequence analysis of the constructs. Plasmid was purified
using the QIAprep miniprep kit following the protocol available with the kit.

3.3.3 Enzyme expression and purification
Competent E. coli BL21DE3 Codon Plus cells were transformed with pET-15b
carrying either the C112S or C112A mutant FabH insert. Transformants were grown in
LB medium to an absorbance of 0.4–0.6, induced with 0.1 mM isopropyl-β-dthiogalactopyranoside, and incubated for an additional four hours at 37 °C. Cells were
harvested by centrifugation at 10,000 g for ten minutes at 4 °C and stored at −20 °C
overnight. After lysis with lysozyme on ice for 30 minutes, cells were sonicated on ice
and then centrifuged at 12,000 g for 30 minutes at 4 °C. The supernatant was loaded onto
a Hitrap chelating 5 ml column and washed with a gradient step from 0 mM to 120 mM
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imidazole in 50 mM sodium phosphate buffer (pH 8.0) with 300 mM sodium chloride.
FabH was eluted with 1 M imidazole under the same buffer conditions. The high
concentration of imidazole employed in the washing step improves the homogeneity of
the mtFabH band as assessed by SDS-PAGE analysis. The mtFabH was desalted in 100
mM sodium phosphate buffer (pH 7.0), and kept at 4 °C overnight. Protein was
concentrated in centricon tubes and assayed by Bradford assay using BSA as standard.
For crystallization, the concentration of mtFabH used was in the range of 4–15 mg/ml.

3.3.4 Crystallization, data collection and structure determination
Note: This part of the project was kindly performed by Dr. Faik Musayev, Dr. Tonie H. Wright and Dr. J.
Neel Scarsdale.

Crystallization conditions were initially screened at room temperature using the
Hampton crystal screen kits and the hanging drop method. Small crystals of apo-mtFabH
(C112A) were obtained with a number of precipitants, and further refinement of
conditions gave promising diffracting crystals from ammonium formate and sodium
chloride as precipitants. Optimal crystals were obtained from drops made from 3 µl of
protein solution at 4 mg/ml in 100 mM sodium phosphate buffer (pH 7.5) to which was
added 3 µl of reservoir solution consisting of 2 M NaCl and 100 mM sodium Mes buffer
(pH 6.5). Crystals were cryoprotected in solutions containing 100 mM sodium Mes buffer
(pH 6.5), 2 M NaCl and 28% glycerol, the final concentration of glycerol being reached
in two steps of 45 seconds each before flash cooling in the liquid nitrogen stream.
Crystals diffracted to a resolution limit of 1.85 Å on a Rigaku rotating anode X-ray
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source run at 50 kV, 100 mA equipped with Osmic confocal optics. A total of 110 frames
of 1.3° oscillations were measured using an RAxisII image plate detector. Oscillation
data were integrated with MOSFLM and merged with SCALA. Data collection statistics
are summarized in Table 4.
The complex of mtFabH (C112A) with lauroyl-CoA was prepared by mixing a
mtFabH solution with 50 mM lauroyl-CoA in doubly distilled H2O. The best crystals of
the C112A–lauroyl-CoA complex were obtained from 1.6 M ammonium formate in 100
mM sodium Hepes buffer (pH 6.5). The plate form crystals reached maximum size of
about 0.05 mm×0.1 mm×0.15 mm in two to three days. To minimize the effect of
hydrolysis during crystallization, data were collected on crystals as soon as they reached
sufficient size. Crystals were cryoprotected for a few seconds in a solution containing 2.7
M ammonium formate, 0.4 mM lauroyl-CoA, 14% glycerol, 100 mM sodium Hepes (pH
6.5), followed by quick transfer to a similar solution containing 3.5 M ammonium
formate and 28% glycerol and freezing at 100 °K in the nitrogen stream. The crystals
diffracted beyond 2.3 Å resolution and data sets of 135 oscillation frames were collected
with a step size of 2.5°. Oscilllation data were integrated and merged with BIOTEX.
A model consisting of the biological dimer from our structure of mtFabH (RCSB
entry 1HZP)27 was used as a search model for molecular replacement for both the
liganded and unliganded data sets. A cross-rotation search was carried out using the fast
direct search protocol as implemented in CNS version 1.0.71 For the unliganded data set,
solutions corresponding to the highest peaks from the cross-rotation search were used as
input to a translation search as implemented in CNS version 1.0. Inspection of initial
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Table 4: Data collection and refinement statistics for mtFabH C112A and C112A.lauroyl-CoA
(C112A/LCOA) structures

Space Group
Unit Cell

C112A

C112A●LCOA

P212121
55.25,109.01,110.98,
90.,90.,90.
1.85
0.044/0.14
9.1/5.0
0.98/0.98
56576
4.6
26.7
1.44

P1
55.57,63.19,55.33,1
13.2,100.8,92.7
2.3
0.073/0.26
8.7/1.9
0.92/0.90
28398
2.9
46.6
1.77

Data Collection

Resolution (Å)
Rmerge1 overall/highest resolution shell
<I>/<F(I)> overall/highest resolution shell
Completeness overall/highest resolution shell
Nobs
Multipliciity
Wilson Plot B (Å2)
Optical Resolution (Å)2
Rwork3 overall/highest resolution shell
Rfreec overall/highest resolution shell
Completeness, overall/highest resolution
shellc
<B>(Å2)
Nwork
Nfree
Natoms
Ndegrees of freedom Torsion Angle Dynamics
Rmsd from ideal:
bond length (Å)
bond angles (o)
Ramachandran Plot
Most favored(%)
Additionally Allowed(%)
Generously Allowed(%)
Forbidden(%)
Cruickshank’s Diffraction Precision
Indicator4
Estimated Maximal Coordinate Error

Refinement
0.186/0.219
0.208/0.247
0.975/0.809

0.206/0.333
0.247/0.412
0.950/0.757

13.2
50770
5143
5391
2277

37.3
26967
1431
5203
2321

0.007
1.085

0.008
1.323

90.4
8.9
0.4
0.4
0.167

89.5
9.8
0.7
0.0
0.493

0.059

0.218

1

Rmerge = ΣΣi Ih-Ihi / ΣΣi Ih where Ih is the mean intensity of reflection h. All data with
I>-3F are included.
2

W = (F2Patterson + F2sph)1/2 the expected minimum distance between two resolved atom
peaks

3

Calculated with all reflections

4

σ(x) = (Natoms/Nobs)1/2c–1/3dminRfree
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2mFo−dFc maps generated with phases from the molecular replacement solutions
indicated the presence of broken density in the putative acyl and pantetheinate channels
of both monomers consistent with the binding of lauroyl-CoA in the C112A-lauroyl-CoA
crystal. No significant density was observed in maps generated for the unliganded crystal.
Models were refined iteratively using simulated annealing and torsion angle dynamics as
implemented in CNS version 1.0 coupled with TLS71 and positional refinement in
REFMAC572 followed by manual rebuilding into 2mFo−dFc, mFo−dFc and 2mFo−dFc
composite omit maps using the programs O,73 TOM or Xfit.74 In the final stages of
refinement, 556 and 197 water molecules were added to the unliganded and liganded
structures, respectively, on the basis of the presence of peaks with heights >3σ in the
mFo−dFc maps. During iterative rebuilding, residue geometries were monitored via
PROCHECK, WHATCHECK75 and OOPS2,76 while van der Waals contacts and
hydrogen bonds were monitored using PROBE77 as integrated with Xfit. Model
coordinate errors were estimated using Cruikshank's diffraction precision indicator as
implemented in SFCHECK.78

Accession Numbers:
Coordinates for the mtFabH C112A mutant and C112A + lauroyl-CoA have been
deposited in the Protein Data Bank (accession codes 1U6E and 1U6S)
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3.4 Results
3.4.1 Electron density interpretation
To obtain a stable complex of lauroyl-CoA with mtFabH, we made both C112A
and C112S mutants to suppress transacylation activity to the active-site cysteine.
Complexes of lauroyl-CoA with both the C112A and C112S mutants were made in
solution and crystallized under significantly different conditions in similar but nonidentical lattices. Both electron density maps showed density in the CoA channel and in
the putative acyl-binding channel of each subunit of the homodimer, but the density for
the C112S mutant was weaker than that for C112A. Only the structure of the C112A
ligand complex is described and discussed here. The structure of the unliganded mtFabH
(C112A), whose conditions of crystallization and lattice type are completely different
from those of the wild-type, is essentially identical with that of the wild-type mtFabH
previously described with one minor exception. The higher resolution of this structure
revealed a bend in helix Cα1 (for nomenclature, see Davies et al.62) between residues 218
and 221 not reported earlier.27 This bend is not present in the corresponding helix of E.
coli FabH and may be a consequence of lattice interactions in the mtFabH (C112A)
structure (see next section). Crystal parameters and statistics for data collection and
refinement of the unliganded and liganded crystal forms of mtFabH (C112A) are shown
in Table 4.
Electron density for the lauroyl-CoA ligand in complex with C112A mtFabH was
readily fit to each subunit of the homodimer in the omit and 2Fo−DFc maps. Electron
density for the adenosine-3′-phosphate moiety of CoA is almost complete in the A
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subunit, but is broken in several places in the composite omit map of the corresponding
site of the B subunit. There is a break in electron density at the pyrophosphate-ribose
linkage of the CoA in both subunits (Figure 17). The descriptions that follow pertain to
the model for lauroyl-CoA in the A subunit binding site, but those of the B subunit are
very similar. There are no significant differences in conformation between the two
subunits of the biologically functional homodimer of either the unliganded or complexed
mtFabH, as was also observed for complexes of E. coli KAS I covalently66 bound to C10
and C12 acyl groups and E. coli FabH64 with bound CoA.

Figure 17: Composite omit map electron density for lauroyl-CoA bound to subunit A of mtFabH
homo-dimer.
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3.4.2 Packing of FabH dimers in the crystal lattice
The tight functional FabH homodimers are related to each other in the triclinic
lattice by a pseudo-dyad axis parallel with the dyad of the functional homodimer (Figure
18 (a)). Although much smaller in area than the contact surface between the monomers of
the biological homodimer, the contact area between non-crystallographic dimers is not
negligible (1535 Å2). It is formed across a local dyad by pairwise interactions between
helix Cα1 of one monomer (residues 210–231) and helix Cα2 (residues 248–259) and
part of helix L1α2 (28–35) of an adjacent monomer. A consequence of this interaction is
that the 3′-phosphoryl-adenosine pyrophosphate groups of CoA in monomer subunits of
different functional dimers are in close proximity across this local pseudo-dyad (Figure
18 (b)). The CoA adenosine nucleotide group of subunit A lies immediately next to this
pseudo-dyad, which appears to force a displacement of the corresponding part of the
ligand in the opposing B subunit. We infer that the local static disorder in the 3′phosphoadenosine pyrophosphate groups of the CoA in each monomer is a consequence
of this close approach of polyanionic groups.
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Figure 18: (a) Model of the mtFabH dimer with lauroyl-CoA (ball and stick models: blue in subunit A
and magenta in subunit B). Arrow 1 denotes the non-crystallographic 2-fold rotation axis relating the
monomers of the functional dimer; arrow 2 denotes a distinct pseudo-2-fold rotation axis relating the
functional dimers. (b) Contact region of two functional homodimers of the asymmetric unit: The
proximity of adenosine triphosphate groups of lauroyl-CoA is depicted at the non-crystallographic 2-fold
rotation axis (2) displayed in (a).
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3.4.3 The lauroyl binding channel
Electron density for the lauroyl group in the mtFabH–lauroyl-CoA structure is
clear and shows this chain lying in the channel hypothesized from the unliganded
mtFabH structure (Figure 17). The lauroyl chain is extended, but with a bend at C7–C8
which lies between Thr (B87) and Thr (A145). A similar bend at C6 was observed in
structures of decanoyl and dodecanoyl groups in complex with KASI and was attributed
to the presence of Phe201 in the acyl channel.66 As noted earlier,27 Thr87 plays a
permissive role in opening this channel to longer acyl chains, in contrast to E. coli FabH,
in which residue 87 is a phenylalanine, which restricts the acyl chain length to four
carbon atoms or less. There is sufficient room at the distal end of the lauroyl chain to
accommodate four more carbon atoms, consistent with the observed in vitro activity of
mtFabH toward myristoyl- and palmitoyl-CoA substrates, as well as lauroyl-CoA.26 The
acyl carbon of the lauroyl group is juxtaposed at a distance of 2.20 Å to the modeled
Cys112 Sγ of wild-type mtFabH overlaid on the Ala112 mutant structure, and the
carbonyl oxygen makes hydrogen bonds of unequal length (3.01 Å and 2.66 Å) to the
main-chain –NH– of A112 and A306 (Figure 19). This oxyanion hole is a conserved
feature of the ketoacyl synthases and stabilizes the inferred tetrahedral intermediate.
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Figure 19: Model centered on the lauroyl acyl group linkage to CoA in subunit A showing the mutant
active-site alanine overlaid on the wild-type active-site cysteine A112(C)). Dotted lines are hydrogen bonds
from proton donors of the oxyanion hole to oxygen of the acyl group.

3.4.4 Conformation and interactions of coenzyme A
The CoA part of lauroyl-CoA lies in the channel in which a putative lauric acid
binds to the unliganded wild-type mtFabH structure. Although this density is contiguous,
except at the pyrophosphate linkage, and has structural features through most of its
length, it is not sufficiently well resolved to be unambiguously fit by the CoA model. The
model of the CoA from the ecFabH complexes cannot be fit throughout to the electron
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density of the mtFabH–CoA structure: the mercaptoethylamine and nucleotide
pyrophosphate portions of the CoA in the mtFabH–lauroyl-CoA complex differ
significantly in position and conformation from those observed in the ecFabH–CoA
complexes, while the pantetheinate parts appear to be more similar (Figure 20).

Figure 20: Stereo view of amino acid residues in proximity to the bound CoA portion of lauroylCoA in the A subunit of mtFabH (a) and of CoA bound to E. coli FabH (b).
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Most of the interactions of CoA with mtFabH occur at the distal adenosine
nucleotide terminus, which lies at the mouth of the CoA binding channel. The adenine
ring of CoA is sandwiched between the planes of Trp32 and the guanidinium group of
Arg151, as was observed for the ecFabH–CoA complex,63 and the adenine amino group
makes a hydrogen bond to Oγ of Ser28. This intercalation of the adenine ring requires
unstacking of the Trp32 and Arg151 side-chains of the unliganded FabH structure on
binding of the cofactor ligand. The 3′ phosphoryl groups of the CoA in the A subunit
interact with Arg151 from the A subunit and also from a lattice-related B subunit across
the non-crystallographic-dyad axis (2) described above. Density for the ribose
pyrophosphate of the CoA in the mtFabH–lauroyl-CoA complex is broken at the
pyrophosphate, but it is clear that the model of CoA derived from the ecFabH–CoA
complexes cannot be fit to it. This is likely due to the close crystal lattice contacts across
the non-crystallographic dyad described above in the mtFabH–lauroyl-CoA complex.
This dyad lies between the 3′-ribose phosphate groups of CoA in different dimers in the
lattice and the juxtaposition of these two anionic groups appears to induce static disorder
at this site. The high temperature factors for the CoA in the mtFabH complex indicate
some disorder in the cofactor and are consistent with the paucity of interactions between
the cofactor and the protein. The temperature factors for protein groups lining this
channel are near the mean for the overall structure, further confirming that the disorder is
confined to the cofactor. The temperature factors for the CoA moiety in the channel are
not an artifact of erroneous occupancies, since the temperature factors for the lauroyl
group are much lower than those of the CoA. In the structure of the ecFabH–CoA
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complexes, the temperature factors for those parts of the cofactor visible in the electron
density map are only slightly higher than those for the protein. These observations are
consistent with a loosely bound CoA in the mtFabH–lauroyl-CoA complex. The possible
origins and implications of this are discussed below.

3.5 Discussion
As a regulated catalyst of the first step in an essential biosynthetic pathway, FabH
has been identified as a potential target for development of new antibacterial agents. The
distinctions between the monomeric type I FAS of animals and the type II dissociated
FAS of bacteria offer the prospect that a target-specific antibiotic would discriminate
between host and pathogen. The crystal structure described here is the first of an intact
substrate complex of FabH with an acyl-CoA, and provides a template for the design of
possible inhibitors of this vulnerable class of enzymes.
Previous attempts to determine the structure of complexes of ecFabH with acylCoA (acetyl and malonyl) prepared by incubation either failed to show electron density
for the acyl group or were transacylated.63 Electron density was visible, however, for the
CoA ligand in these structures and it provided information on the mode of cofactor
binding in the product complex. Crystal structures for two acetyl–CoA complexes with
ecFabH (1HNH, 1HND) have been determined. In one, the acetyl group is covalently
bound to the active-site cysteine Sγ, but is missing in the other, though the CoA is
retained in the binding channel of both. In the malonyl–CoA complex with ecFabH
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(1HNJ), the malonyl group is not observed and was inferred to be disordered or to have
hydrolyzed during preparation, but CoA is observed in the binding channel. The acetyl–
CoA complex with ecFabH is therefore a product complex of the initial transacylation
step of the reaction, probably stabilized by the retention of bound CoA, which prevents
ingress of water that would hydrolyze the thioester linkage. The other two ecFabH
complexes, while not on the reaction pathway, confirm the observed conformation of the
CoA as that for product complex, except for variation in the tail from C7 of the
pantetheinate through the mercaptoethylamine group.
In contrast to ecFabH–CoA complexes, formation of CoA crystal complexes with
mtFabH, either by soaking or cocrystallization, has been problematic. When lauroyl–CoA
is used as substrate to try to prepare substrate or product complex with wild-type
mtFabH, only lauric acid is observed to bind in the acyl channel. This latter result
suggests that the lauroyl-thioester intermediate is hydrolyzed by water that can enter the
active-site in the absence of bound CoA and is consistent with a low affinity of CoA for
its binding channel in mtFabH relative to ecFabH. By utilizing a catalytically disabled
FabH mutant, C112A, we have been able to visualize the intact lauroyl–CoA substrate
bound to mtFabH. The acyl linkage between the lauroyl group and the βmercaptoethylamine of the CoA is clearly visible in our electron density map. The length
of the acyl channel in the mtFabH–lauroyl-CoA complex is consistent with the substrate
specificity of this enzyme in solution and confirms our hypothesis for the unique role of
this type II FabH in the biogenesis of long chain fatty acids in M. tuberculosis.27
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Of the few known structures64,69,70 and inferred models79 of CoA complexes with
ketoacyl-synthases, the CoA of the mtFabH–lauroyl-CoA complex described here
appears to be the least stabilized in its binding site. The observed difference in binding
mode of CoA between the E. coli and mtFabH complex structures could arise from any of
several sources: (i) differences in the residues that interact with the CoA in the two
FabHs; (ii) effects of the CoA-linked lauroyl group; (iii) distinctions between substrate
and product complexes; (iv) the influence of lattice interactions on the conformation of
CoA.
There are two amino acid differences between ecFabH and mtFabH in the
pantetheinate binding part of the CoA channel: L189, which is Ile in mtFabH, and M207,
which is Leu in mtFabH. HINT analysis80 of the ecFabH and mtFabH complexes with
CoA shows that these two residues make unfavorable polar-hydrophobic interactions
with the pantetheinate as built in the mtFabH complex. These two unfavorable contacts,
plus several favorable ones in the ecFabH–CoA complex that are not made in the
mtFabH–lauroyl-CoA complex are consistent with more stable binding of CoA in the
ecFabH–CoA complex than in the mtFabH.
It is possible that binding of the lauroyl group affects the conformation of the
CoA in the mtFabH–lauroyl-CoA complex relative to that observed in the ecFabH–CoA
complex. This seems unlikely for substrate acyl–CoA complexes, since the
stereochemical requirements for acylation will be the same for small and large acyl
groups. However, because we are comparing a substrate complex (mtFabH–lauroyl-CoA)
with a product complex (ecFabH–CoA), differences in structure could be a consequence
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of differences between these chemically distinct intermediates on the reaction pathway.
The apparent higher stability of the CoA in the ecFabH complexes than in the mtFabH–
lauroyl-CoA complex may reflect differences in the energetics of binding substrate
versus product. These differences are most likely to be manifested at the
mercaptoethylamine part of the CoA where chemical bonding differs in the two
complexes. This could explain the major differences in conformation of this part of the
CoA between the ecFabH–CoA and mtFabH–lauroyl-CoA complexes. In this connection,
we note that the overall conformation of the lauroyl–CoA ligand in the mtFabH complex
differs from that of two other long-chain acyl–CoA complexes in the RCSB database
(1H9G, 1IYK). This is consistent with a relatively flat energy surface for CoA conformers
and a dominant role for the protein binding site in determining the conformation of bound
CoA.
Finally, the close lattice contacts involving the nucleotide ends of CoA in the
mtFabH–lauroyl-CoA complex are likely to induce changes in conformation of the CoA
in each copy of the complex. This is a probable cause for the difference in conformation
of the ribose pyrophosphate group in the ecFabH–CoA complex versus that in the
mtFabH–lauroyl-CoA complex. The electron density for this part of the CoA in the latter
complex is broken, which is consistent with disorder imposed by the close contact of
anionic groups. Nevertheless, density for the adenine ring is complete in subunit A and
substantial though incomplete in subunit B, indicating that this interaction is a highly
stabilizing one and can tolerate disorder in immediately contiguous groups.
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The difference in apparent stability of bound CoA between the mtFabH–lauroylCoA and the ecFabH–CoA complex may reflect compensating contributions of the acyl
and CoA moieties that result in isoenergetic binding of both long and short acyl-CoA
substrates. The longer acyl chain of mtFabH substrates will be more stable in its
extended, sequestered hydrophobic binding channel than an acetyl group and could
thereby anchor the CoA portion of the substrate, which may have lower stability bound to
the mtFabH than to ecFabH. It may be more important to note that neither the ecFabH
product complex nor the mtFabH substrate complex described here shows numerous or
strong stabilizing interactions of bound CoA in the CoA channel. This may reflect a
requirement for facile dissociation of the product CoA ligand after the initial
transacylation step of the reaction and could help drive this reaction, which is a ground
state exchange with little intrinsic energy difference between substrate and product.
These arguments and the structure of the complex of lauroyl-CoA with mtFabH
raise two questions relating to the trajectory and energetics of long chain acyl group
binding to FabH. For instance, how does the long acyl chain enter the seemingly
restricted binding channel in mtFabH. If the acyl group threads through the CoA channel
past the active-site cysteine to reach the buried acyl channel, what drives that
translocation? And how is a long chain ketoacyl-ACP product dissociated from the
enzyme? In the case of long chain acyl-CoA binding, differential stability of the acyl
group in its highly hydrophobic specificity pocket could promote its migration beyond
the CoA channel, culminating in a substrate complex stabilized primarily by the
sequestered acyl group and the nucleotide end of the CoA. An alternate mechanism
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where the substrate entry is facilitated by conformational changes in the enzyme is also
possible. Following transacylation to the active-site cysteine, the paucity of interactions
of the CoA in the pantetheinate binding channel would permit its ready dissociation. This
might be further assisted by disruption of the adenine nucleotide interaction of CoA at the
mouth of the channel through competition with incoming malonyl-ACP. However,
following decarboxylation and condensation by mtFabH, a long-chain ketoacyl-ACP
product complex would be stabilized in its bound state due to the buried position of the
acyl group in the hydrophobic channel. Dissociation of this long-chain ketoacyl-ACP
product would seem to require facilitating mechanisms.

3.6 Conclusions:
The crystal structure of this complex confirms our identification of the acyl
binding channel and shows the mode of binding of the acyl group in this channel and of
CoA in the other channel. This supports the hypothesized function for this FabH as an
initiator of mycolate biosynthesis utilizing acyl-CoA chains of length 12–16 carbon
atoms. This structure also suggests distinctions from the ecFabH in its interactions with
CoA and poses several important questions regarding the binding of substrates and
energetics of the FabH reaction mechanism.
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4. Probing reactivity and substrate specificity of both subunits of the
dimeric Mycobacterium tuberculosis FabH (mtFabH) using alkyl-CoA
disulfide inhibitors and acyl-CoA substrates

4.1 Summary
The dimeric Mycobacterium tuberculosis FabH (mtFabH) catalyses a Claisentype condensation between an acyl-CoA and malonyl-Acyl Carrier Protein (ACP) to
initiate the Type II Fatty Acid Synthase cycle. To analyze the initial acylation of mtFabH
with acyl-CoA, we challenged it with a mixture of C6-C20 -CoAs and the ESI-MS analysis
showed reaction at both subunits and 'a strict specificity for C12-CoA. Crystallographic
and ESI-MS studies of mtFabH with decyl-CoA disulfide inhibitor revealed the decyl
chain bound in acyl-binding channels of both subunits through disulfide linkages to the
active site cysteines. These data provide the first unequivocal evidence that both subunits
of mtFabH can react with substrate or inhibitor. The discrepancy between the observed
C12-CoA substrate specificity in the initial acylation step and the higher catalytic
efficiency of mtFabH for C18-C20 -CoA substrates in the overall mtFabH catalyzed
reaction suggests a role for M. tuberculosis ACP as a specificity determinant in this
reaction.
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4.2 Introduction:
Enzymological studies have shown that mtFabH can utilize a wide range of C12C20 acyl-CoA substrates,26,27,57 which distinguishes it from FabH in other type II FAS
systems that typically utilize C2-C6 acyl-CoA substrates.26,81 Initial studies using
malonyl-E. coli ACP (ecACP) as the malonyl-ACP substrate of mtFabH indicated a
broad C8-C20 acyl-CoA substrate specificity.26 The C10-C12 acyl-CoA substrates were
processed most efficiently (6-8 nmol/min/mg), while the reaction rates using the putative,
physiological longer chain (C18-C20) acyl-CoA substrates were significantly lower (<0.6
nmol/min/mg).57 This same pattern has recently been observed in assays using malonylCoA in place of malonyl-ACP [data in publication]. However, mtFabH has a higher
turnover number toward longer chain C14-C20 acyl-CoA substrates (9-10.5 nmol/min/mg)
in the overall reaction when cognate ACPM is used in the assay.57 The basis for this
differential efficiency in processing longer chain acyl-CoA substrates remains unclear.
The crystal structures of mtFabH and an array of mutants have raised other
questions relating to processing of longer chain C18-C20 acyl-CoA substrates. (see chapter
3 and ref.

27,57

) mtFabH has a closely similar topology and active site architecture to that

of E. coli FabH (ecFabH). However, whereas ecFabH has a small acyl binding pocket
contiguous with the pantetheinate binding channel, the substrate binding pocket of
mtFabH is L-shaped, consisting of a solvent accessible pantetheinate binding channel
connected to a closed, elongated acyl binding channel. The active site catalytic triad
(Cys112-His244-Asn274) lies at the junction of the two arms of the “L”. The closed
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distal end of the acyl binding channel imposes an upper length limit of C16 for acyl-CoA
substrates in the static mtFabH structure. An mtFabH crystal structure of the Michaelis
complex of dodecanoyl-CoA with an inactive C112A mutant (chapter 3) clearly shows
substrate bound in the “L” shaped channel of each monomer, with the dodecanoyl group
in the acyl binding channel. The length of this channel raises the as yet unanswered
question of how longer C18-C20 acyl-CoA substrates bind and acylate mtFabH.
Previous observations made with both the ecFabH and mtFabH raise a third
question of whether both monomers of the mtFabH homodimer are acylated. In the case
of the ecFabH crystal structures,63,82 including an unliganded tetragonal form of ecFabH
in which several polypeptide segments that contribute to the structure of the substrate
binding site and to the dimer interface are disordered, indicate structural equivalence of
the two monomers. However, we have recently obtained a crystal structure of the
inhibition complex of ecFabH with a methyl-CoA disulfide (MeSSCoA) in which there is
a methyl disulfide linkage to the active site cysteine in only one monomer of the dimer.83
Attempts to obtain a crystal structure in which both subunits are modified have thus far
been unsuccessful. Kinetic analysis of MeSSCoA inhibition suggests that both subunits
of ecFabH are modified via a biphasic process in which one subunit is modified quickly
and the second more slowly. A similar biphasic acylation of the ecFabH with acetyl-CoA
substrate was also observed. These observations have led to the proposal that ecFabH
exists in an open form that orders around either a substrate or inhibitor in one subunit,
and in so doing retards binding of ligand to the second subunit.83 Similar asymmetry of
ligand binding and disorder→order transitions may occur in mtFabH and may severely
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hamper ligand binding and reaction at the second subunit. Indeed, it has been reported
that acylation studies carried out using the mtFabH and radiolabeled decanoyl-CoA (in a
molar ratio of 1:2.3) result in only 23% acylation of the protein57. Our complex of the
mtFabH C112A mutant with lauroyl-CoA indicates structural identity of the two
monomers (as seen for all mtFabH structures) and also that under prolonged incubation
dodecanoyl CoA can bind in both subunits of the enzyme (chapter 5)
In this work we have addressed these questions of mtFabH specificity and
mechanism using ESI-MS and crystallography to monitor the reaction of the wild type
mtFabH with both a decyl-CoA disulfide inhibitor and a wide range of C6-C20 acyl-CoA
substrates. We have shown conclusively that substrate and inhibitor react with the active
site cysteines in both subunits of the mtFabH dimer. We have also probed for the first
time the substrate specificity of the acylation step catalyzed by mtFabH (previous
analyses have only assessed this step indirectly by analysis of the overall reaction), and
shown clear preferential formation of a modified enzyme using a C12 dodecanoyl-CoA.
These findings imply a role for ACPM in determining the specificity of the mtFabH
reaction and the profile of the product pool and provide new and essential data for the
formulation of a model for mtFabH catalysis.

4.3 Experimental procedure
4.3.1 Materials
Long chain acyl-CoAs, coenzyme-A, imidazole, dithiothreitol (DTT) (Sigma);
Crystal screens I and II (Hampton Research).
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4.3.2 Enzyme expression and purification
The wild type and C112A mtFabH proteins were overexpressed in E. coli as
discussed in chapter 3.

4.3.3 Synthesis of decylSSCoA
DecylSSCoA was synthesized using standard procedures83 and generously
provided by Dr. Mamoun Alhamadsheh.

4.3.4 ESI-MS analysis
A solution of wild type or mutant mtFabH in sodium phosphate buffer (50 mM,
pH 7.0, 15 % glycerol) was incubated at room temperature for 40 min with either an
equimolar mixture of C6, C8, C10, C14, C16, C18, and C20 acyl-CoAs (ratio of mtFabH
monomer to each substrate was 1:5) or decylSSCoA (ratio of mtFabH monomer: inhibitor
of 1:5). Excess ligand in both incubations was then removed using Pierce spin desalting
columns and the enzyme concentrated in a Microcon concentrator (50 kDa cutoff) and
stored at –20˚C until the ESI-MS analysis was performed. The thawed samples were
diluted to a concentration of approximately 1 pm/µl with 50% methanol/0.1% formic acid
and analyzed by ESI-MS using a Quadrupole Time-of-flight mass spectrometer under
standard procedures and the peaks were deconvoluted by the Bayesian protein reconstruct
tool (in the Bioanalyst QS 1.1 software package).
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4.3.5 Crystallization conditions (Kindly performed by Dr. Faik Musayev)
Prior to crystallization trials, the protein solution was concentrated to
approximately 15mg/ml by ultrafiltration using a Microcon concentrator (Amicon) with a
30 kDa cutoff. The enzyme (15mg/ml in 100mM sodium phosphate buffer, pH 7.0) and
inhibitor (13mM in methanol) solutions were mixed in a 1:3 molar ratio and incubated on
ice for 2 hours. Crystallization of the mtFabH- C10SSCoA was achieved using the
hanging-drop vapour-diffusion technique. Initial crystallization conditions were screened
using Crystal Screen and Crystal Screen II from Hampton Research at 290K. Crystals
grew within two-three weeks from PEG-4K and PEG-10K and further variation of
conditions yielded two optimal crystal forms.

Both were obtained by mixing 2µl of

protein-inhibitor complex solution with an equal volume of reservoir solution and
equilibrated over the precipitant well at 295K. The first crystal form was obtained in 25%
(w/v) PEG-8K, 0.1 M ammonium sulfate and 100mM Na Cacodylate, pH 6.5 and grew to
maximum dimensions of ~ 0.04 x 0.02 x 0.06 mm within three weeks. These crystals
have space group P1, with unit cell parameters a = 49.06, b = 55.76, c = 63.16 A, α =
92.8, β = 98.8, γ = 111.80. The second crystal form was crystallized in the presence of
18% PEG-10K (w/v) and 100mM Na Hepes, pH 7.0 and grew to 0.05 x 0.03 x 0.3mm
within three weeks. These crystals have space group C2221 with unit cell parameters a =
67.65, b = 89.36, c = 232.01 A.
Data sets for both crystal forms were collected at 100°K on an R-Axis IV++
image-plate detector using CuK α X-rays (λ = 1.54 A) from a Rigaku MicroMax

TM

–

007 X-ray source equipped with MSC Varimax confocal optics operating at 40kV and
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20mA. The crystals were transferred with a cryoloop into corresponding mother liquor
solutions containing additional 15-20% glycerol and 0.1mM inhibitor for ~10s and
subsequently flash-cooled in a cold nitrogen-gas stream from an X-stream cryosystem
(MSC). Both crystal forms diffracted to 2.5Å resolution, but the data-collection statistics
were better for the second crystal form, which was used for structure determination and
refinement. Coordinates of the final refined structure were deposited in the RCSB with
accession number 2QX1.

4.4 Results and discussion.
4.4.1 Acylation of mtFabH by a mixture of acyl-CoA substrates
mtFabH was treated with a mixture of acyl-CoA substrates ([C6-C20]-CoA) in the
absence of ACP and the resultant acylated mtFabH was analyzed using ESI-MS. The
ratio of each acyl-CoA to the mtFabH monomer is ~ 5:1. The experimental ESI mass
value for native mtFabH monomer is 36903 Da (compared to a theoretical value of
36904.7 Da) (Figure 21a). Treatment of mtFabH with this mixture of acyl-CoAs for 40
minutes at room temperature resulted in total modification of the enzyme as evident from
the complete absence of native mtFabH at 36903 Da (Figure 21b). These data provide
the first evidence that both monomers of the mtFabH dimer are acylated during reaction.
The appearance of a major peak at 37085.0 Da corresponds to the addition of one
dodecanoyl group (from dodecanoyl-CoA) to the mtFabH enzyme (experimental mass
shift of +182 Da compared to theoretical mass value of +183 Da). Surprisingly, under
our assay conditions, we did not observe mtFabH acylation with any other acyl-CoAs.
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Figure 21: Reconstructed ESI-TOF mass spectra of the incubation products of WT mtFabH with a
mixture of acyl-CoAs (C6-C20). (a) Mass spectrum of untreated WT mtFabH (control). (b) Mass spectrum
of WT mtFabH treated with acyl-CoA mixture.
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The apparent selective formation of the dodecanoyl product is puzzling given the
relatively similar rates of reaction for the overall mtFabH catalyzed reaction with a range
of acyl-CoA substrates.57 However, it is consistent with our repeated observation of
adventitiously bound dodecanoic acid in the substrate binding channel of crystal
structures of recombinant mtFabH expressed in E. coli. Also, in trying to prepare
Michaelis complexes of mtFabH C112A mutant with either tetradecanoyl-CoA or
hexadecanoyl-CoA for co-crystallization, we have invariably obtained a complex with
dodecanoyl-CoA in the binding site (unpublished data). We cannot exclude the
possibility that the tetradecanoyl- or hexadecanoyl- groups are present in the determined
crystal structures but are disordered at their terminal pairs of methylene groups.
However, this is made less likely by the determination from HPLC analyses of these
longer chain acyl-CoA substrate preparations, that a dodecanoyl-CoA impurity (≤2%) is
present, which we infer binds preferentially to the mtFabH during crystallization.
Together these observations suggest that the mtFabH Michaelis complex and subsequent
acyl-enzyme intermediate thermodymamically favor the dodecanoyl-CoA substrate.

4.4.2 Thio-Alkylation of mtFabH by decylSSCoA
As noted above, MeSSCoA inhibits ecFabH through a disulfide exchange
mediated transfer of the MeS- group to the sidechain sulfur of the active site Cys112 of
the enzyme. We also prepared decylSSCoA, which in preliminary experiments did not
inhibit ecFabH but was effective against mtFabH.83 To determine whether this class of
inhibitors acts by the same mechanism on mtFabH as on ecFabH, the inhibition of
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mtFabH by decylSSCoA was analyzed using ESI-MS under similar conditions to those
described above for the acylation reaction (Figure 21).

S S CoA
a

C 10H 21S
theoretical 173 Da
experimental 176 Da

b

Figure 22: Reconstructed ESI-TOF mass spectra of the incubation mixture of WT mtFabH and
decylSSCoA. (a) Mass spectrum of untreated WT mtFabH (control) (b) Mass spectrum of WT mtFabH
treated with decylSSCoA disulfide inhibitor.
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Treatment of mtFabH with decylSSCoA resulted in formation of a modified
mtFabH species (Figure 22B) that correlates well with the addition of a C10S- fragment (a
theoretical mass increase of 173 Da to the mtFabH monomer fragment). The absence of
this peak in C112A mtFabH mutant confirmed that this modification occurs at the active
site cysteine in WT mtFabH (data not shown). Only a fractional modification of the
mtFabH with decylSSCoA was observed, in contrast to the full modification observed
using dodecanoyl-CoA. This observation, taken with the 23% extent of reaction for
decanoyl-CoA with mtFabH,57 confirm a specificity preference for C12 over C10 ligand
binding in the acyl binding channel, but probably also reflects in part a slower reaction
rate of the inhibitor relative to the substrate. This latter is the case for acetyl-CoA and
methylSSCoA inhibitors with ecFabH.83
A co-crystal structure of mtFabH and decylSSCoA showed both of the active site
cysteines of the mtFabH dimer to be modified through disulfide linkage to the decylthiogroup. The decyl group has full occupancy in one subunit and slightly less than full
occupancy in the second subunit. As we and others have frequently observed, CoASH
product is only weakly retained in the pantetheinate channel of FabH – ligand complex
structures. No interpretable density for CoASH was observed in one subunit of the
decylSSCoA complex, while density in the other subunit was largely complete except for
breaks around the pyrophosphate group. CoASH is probably preferentially retained in
this latter channel as a consequence of an interaction of the pyrophosphate group of the
nucleotide with Arg214 of a symmetry-related molecule. The terminal thiol of the
pantetheinate group of this CoASH is 6.1Å from the Cys112 decyl-disulfide and the
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terminal adenine nucleotide group stacks on Trp32 and Arg151 at the mouth of the
binding pocket (Figure 23), as has been observed in other CoASH complexes with FabH.

Figure 23. Backbone structure of mtFabH homodimer (subunits in gold and magenta ribbon) in
complex with C10S- (space filling, cyan = carbon, red = oxygen, blue = nitrogen, orange = sulfur)
covalently linked to the sidechain sulfur of Cys112 (also space filling) in both subunits. CoA is
shown bound in only the A-subunit (gold) also in space filling model.
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4.5 Conclusion
We provide the first evidence that the active site cysteine in both subunits of the
wild type mtFabH dimer is able to react with either a dodecanoyl-CoA substrate or a
decylSSCoA inhibitor. The data clearly demonstrate that binding and reaction at one
subunit does not preclude reaction at the other, but we cannot determine whether binding
and reaction occur at the same rate in both subunits. In the case of ecFabH, reaction at the
second subunit is slower than that at the first.83
In the static crystal structure of wild type mtFabH modified by formation of a
disulfide product with the decylSSCoA inhibitor, the CoA binding channel is the only
obvious access path to the buried acyl-binding channel. Binding and reaction of one of
the mtFabH subunits with substrate or inhibitors via a reptational threading through this
pantetheinate channel and past the active site residues would be energetically
unfavorable. The data however show that this occurs readily to both subunits suggesting
that there is likely an alternative more favorable pathway for binding of substrate or
inhibitor ligand to mtFabH. These observations support the existence of a hitherto
unobserved ‘open’ form of mtFabH, like that proposed for ecFabH,63,83 which provides a
direct, low energy path for substrate or inhibitor entry to the acyl binding channel.
The overall mtFabH catalyzed reaction using malonyl-ACPM has been shown to
use C14-C20 acyl-CoAs at least as efficiently as dodecanoyl-CoA.57 In this current work
we have shown that in the acylation reaction performed with a range of acyl-CoAs
(carried out in the absence of malonyl-ACPM) the mtFabH selectively forms a product
with the dodecanoyl CoA. It has been previously proposed that ACPM modulates the
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substrate specificity of the mtFabH.57 Our current data support this hypothesis and we
propose that ACPM assists in formation of an open mtFabH structure, which facilitates
both binding of longer chain acyl-CoA substrates and also release of the long chain βketoacyl-ACP products.
In conclusion, this and other recent analyses of FabH enzymes suggest that the
model for catalysis provided by current crystal structures is incomplete, and must be
expanded to include significant protein conformational changes which are associated with
the acyl–CoA and specific malonyl-ACP substrates. Further experiments are discussed in
future direction (chapter 7).
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5. Separate entrance and exit portals for ligand traffic in Mycobacterium
tuberculosis FabH

5.1 Summary
Mycobacterium tuberculosis FabH initiates type II fatty acid synthase-catalyzed
formation of the long chain (C16 – C22) acyl-CoA precursors of mycolic acids, which are
major constituents of the bacterial cell envelope. Crystal structures of mtFabH (as
discussed in chapter 3) show the substrate binding site to be a buried, extended L-shaped
channel with only a single solvent access portal. The distal, dead end arm of this channel
binds the acyl moiety of the substrate and the arm proximal to the solvent portal binds the
CoA moiety. Entrance of an acyl-CoA substrate through the solvent portal would require
energetically unfavorable reptational threading of the substrate to its reactive position.
Using a new class of FabH inhibitors, we have tested the alternative hypothesis that FabH
exists in an ‘open’ form during substrate binding and product release, and a closed form
in which catalysis and intermediate steps occur. This hypothesis is supported by mass
spectrometric analysis of the product profile and crystal structures of complexes of
mtFabH with these inhibitors.
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Figure 24: (a) Backbone structure of C112A mtFabH homodimer (gold ribbon) in complex with
lauroyl-CoA (space filling, green = carbon, red = oxygen, blue = nitrogen, yellow = sulfur, magenta
= phosphorous) bound in the buried, L-shaped binding site of each monomer of the dimer.
(adopted from chapter 3)
(b) Expansion of active site residues (gold stick) in 24 (a) with functional atoms (color coded as in
Figure 24 a) and Cys112 modelled from wt mtFabH structure for the lauroyl-CoA (space filling
atoms color coded as in Figure 24 (b) with bound lauroyl-CoA.

5.2 Introduction:
The crystal structure of the Michaelis complex of lauroyl-coenzyme A with an
inactive C112A mtFabH mutant (chapter 3) clearly shows substrate bound in an “L”
shaped channel of each monomer (Figure 24a), with the active site triad (Cys112-His244Asn274) at the junction of the two arms of the “L” (Figure 24 b). Coenzyme A occupies
the solvent accessible, pantetheinate arm of the “L”, while the acyl group occupies the
distal, dead-end arm of the “L”, an extended hydrophobic channel that appears accessible
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only through the pantetheinate channel. Binding of lauroyl-CoA substrate would thus
appear to require migration of the hydrophobic lauroyl chain through the pantetheinate
binding channel and around the bend of the “L” past the hydrophilic and charged
catalytic residues. Formation of the complex in this manner would present formidable
stereochemical and energetic barriers, and dissociation of long chain β-ketoacyl-ACP
reaction product from this buried hydrophobic site via a reversal of this process would
appear to be equally unfavorable.
These considerations have led us to hypothesize that native mtFabH adopts a
hitherto unobserved ‘open’ conformation which offers an alternate pathway with lower
energy barriers for initial substrate binding and final product release. To test this
hypothesis, we prepared inhibitors with one or two hydrophobic arms that occupy either
one or both binding channels, and a reactive group that targets the active site cysteine
(Figure 25). The binding modes of these inhibitors with the wild type mtFabH have been
established by mass spectrometry and x-ray crystallography. These same analyses with an
mtFabH A246F mutant, whose pantetheinate binding channel is blocked, reveal that
inhibitor binding and reaction still proceed efficiently, but only with one arm inhibitors
that bind exclusively in the acyl channel. These experiments provide strong evidence that
mtFabH exists in an open conformation that accepts ligands directly into the acyl binding
channel without entry to the single solvent portal and passage through the pantetheinate
channel of the closed form of the enzyme. These results support a new model for
substrate binding, catalysis and product release in mtFabH.
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5.3 Experimental procedures
5.3.1 Materials
All general chemical supplies not listed below are ordered from standard
companies and were reagent grade or better. The source of specific supplies are as
follows: [2-14C] malonyl-CoA (ARC-528, specific activity 55mCi/mmol) was purchased
from American Radiolabeled Company and lauroyl-CoA (trilithium salt) was purchased
from Sigma. The Reverse Phase (RP) HPLC studies were performed on Amberchrom C18
RP columns from Rohm and Hass Company; trypsin enzyme used was proteomic grade
and was bought from Sigma; PepcleanTM C18 Spin Columns were from Pierce. All
Electrospray Ionization Mass spectrometry (ESI-MS) experiments were performed on
Quadrupole time-of-flight mass spectrometer (model QSTAR XL) from Applied
Biosystems/MDS Sciex which is equipped with a standard ion source from MDS Sciex,
Concord, Canada. The glu-fibrinopeptide used for externally calibrating the QSTAR
instrument in positive ion mode was from Sigma. Grafit 4.012 (Middlesex, United
Kingdom) for data plotting is bought from Sigma.

5.3.2 Enzyme expression and purification:
WT mtFabH and C112A mtFabH are cloned, expressed and purified as described
in chapter 3. The A246F mutations were made on the open reading frame Rv0533c
(mtFabH), which was cloned into the expression vector pET-15b as described
previously.27 Mutants were made according to the protocol provided for the Quikchange

80

XL site-directed mutagenesis kit and primers designed to substitute Phe for Ala246.
Primers were ordered from Integrated DNA Technologies and were, forward 5’-GTG
TTC GTC CCT CAT CAG TTC AAT AGC CGC ATC AAC GAG - 3’ and reverse 5’ –
CTC GTT GAT GCG GCT ATT GAA CTG ATG AGG GAC GAA CAC– 3’. Mutations
were confirmed by sequence analysis of the final constructs. The plasmid was purified
using the QIAprep miniprep kit.
Competent E. coli BL21DE3 Codon Plus cells were transformed with pET-15b
carrying A246F FabH insert. Transformants were grown in LB medium to an absorbance
of 0.4 – 0.6, induced with 0.2 mM isopropyl-beta-D-thiogalactopyranoside, and
incubated for an additional 4 hrs at 37º C. Cells were harvested by centrifugation at
10,000 g for 10 min. at 4 °C and stored at -80 °C until used. After lysis with lysozyme on
ice for 30 minutes, cells were sonicated on ice and then centrifuged at 12,000 g for 30
min. at 4 °C. The supernatant was loaded onto a Hitrap chelating 5-ml column and
washed with a gradient step from 0 to 120 mM imidazole in 50mM sodium phosphate
buffer, pH 8.0 with 300mM sodium chloride. FabH was eluted with 1 M imidazole under
the same buffer conditions. The high concentration of imidazole employed in the washing
step improves the homogeneity of the mtFabH band as assessed by SDS-PAGE analysis.
The mtFabH was desalted in 100mM sodium phosphate buffer pH 7.0, and kept at 4 °C
overnight. Protein was concentrated in Centricon tubes and assayed by Bradford assay
using BSA as standard. For crystallization, the concentration of mtFabH used was in the
range of 4 - 8 mg/ml.
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5.3.3 Synthesis of compounds 1-3:
The syntheses of inhibitors 1-3 were carried out by Dr. Alhamadsheh and kindly
provided in ample amount for this study.

5.3.4 Enzyme assays:
The mtFabH assay was performed as described in chapter 2.

5.3.5 Electrospray Ionization-Mass Spectrometry (ESI-MS) analysis:
5.3.5.1 Sample preparation:
Wild type or mutant mtFabH in sodium phosphate buffer 50 mM, pH 7.0, 15 %
glycerol were first desalted with HPLC grade water using Hitrap desalting column. The
aliquot of enzyme (10-40 µM) and inhibitors 1, 2 or 3 separately (mtFabH dimer:
inhibitor ~ 1:10) were incubated at room temperature for 60 minutes and then excess or
non-covalently adhered inhibitor was desalted using a Pierce spin desalting columns. The
enzyme was concentrated using Microcon concentrator (50 kDa cutoff) that also works as
second desalting step and then stored at –20˚ C until the ESI analysis.

82

5.3.5.2 ESI-MS analysis conditions:
The sample was diluted to 1 pm/µl with 50 % methanol/0.1 % formic acid and
analyzed by a quadrupole time-of-flight mass spectrometer. The instrument was
externally calibrated in the positive ion mode using two fragment ion peaks (m/z
175.1190 and m/z 1285.5444) from the tandem mass spectrum of Glu-fibrinopeptide. The
samples were directly infused into the ion source using a 500 µl syringe at a flow rate of
5 µl/min through red peek tubing (Upchurch). The following parameter settings were
used to acquire mass spectra from m/z 600-1600 in the positive ion TOF/MS mode: spray
voltage, 5500V; curtain gas, 20; GS1 gas, 15; declustering potential (DP), 85 V;
declustering potential 2 (DP2), 15 V; focusing potential (FP), 265 V; accumulation time,
1 s. Typically, spectra were averaged over 120 scans, and the series of multiply charged
ion peaks were deconvoluted by the Bayesian protein reconstruct tool (in the Bioanalyst
QS 1.1 software package) to determine the zero charge masses of the intact proteins. For
all mass calculations, 0.01 % mass accuracy was set as tolerance limit; ie about 3.7 Da
for mtFabH whose monomeric molecular weight is about 37,000.
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5.3.5.3 ESI-MS data analysis:
The theoretical mass of His-tagged WT mtFabH monomer by DNA deduced
amino acid sequence is calculated to be 36904.7 Da. The experimental mass is found to
be 36903 as shown in Figure 26 a. Treatment of mtFabH with inhibitors resulted in
appearance of multiple new species along with their sodium adducts (Figure 26b). The
mtFabH was purified and initially prepared in sodium phosphate buffer and thus up to 4
sodium adducts were readily obtained as evident from the control experiment (untreated
WT mtFabH deconvoluted spectrum, Figure 26 a). All calculations were performed based
on guidelines set forth as described below. The area of most abundant species was
identified and all species with areas encompassing up to 10% of its area was taken into
consideration for calculation of total area. Mass value of control mtFabH (36903 Da) was
subtracted from each mass value obtained and the positive mass difference as indicative
of a particular species being present. Each species and its sodium adducts was
categorized as a single species and percent area of each species was calculated. Mass
differences of more than 1 kDa and negative mass differences were discarded as nonmtFabH related species. The final data was presented with nature of species (unmodified,
trimodified, dimodified, mono-modified and others, for those which can’t be assigned) on
X-axis and percentage of particular species observed is plotted on Y-axis.
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5.3.6 Crystallization, x-ray data collection and structure determination. (This work
was carried out by Dr. Faik Musayev, Dr. Tonie Wright and Dr. J. Neel Scarsdale)

Crystals were obtained by the hanging-drop vapor diffusion method using 4µl
drops consisting of a 1:1 ratio of protein to reservoir solution equilibrated against 600µl
of reservoir solution at room temperature. Protein concentration varied from 4-15mg/ml
in 100mM sodium phosphate buffer, pH 7.0. Inhibitor molecules were dissolved in
methanol to a final concentration of 34mM (1), 25mM (2) and 23mM (3) and mixed with
protein solution at the molar ratios shown in Table 5. Before crystallization, proteininhibitor complex mixtures were incubated on ice for 2 hrs. Crystallization conditions
and lattice parameters for the structures are summarized in Table 5.
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Table 5 Crystal conditions for structures determined in this study (chapter 5)
Inhibitor

Protein

Protein
Conc.

Reservoir solution

(mM)

Protein:
Inhibitor
molar
ratio

No.

Lattice Parameters

Accession No.

(A)

1

WT

0.21

1:3.5

50mM Na Acetate, pH4.6,
2.4M Na Formate

68.03, 88.85, 229.74
sp.gr. C2221

2QNZ

1

A246F

0.11

1:4

100mM Na Hepes, pH 7.5,
1M K/Na Tartrate

67.70, 88.69, 229.90
sp.gr. C2221

2QNY

2

WT

0.15

1:5

100mM Na Mes, pH 6.5,
50mM NaH2PO4/KH2PO4,
1.8M NaCl

68.28, 88.98, 230.25
sp.gr. C2221

2QNX

3

WT

0.4

1:2.5

100mM Na Hepes, pH 7.5,
1M K/Na Tartrate

68.41, 89.12, 233.29
sp.gr. C2221

2QO1

3

A246F

0.21

1:4

100mM Na citrate, pH 5.6,
10% Isopropanol, 18% PEG-4K

55.30, 93.05, 104.72
sp.gr. P212121

2QO0
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For x-ray data collection, crystals were cryoprotected in their mother liquid
solution supplemented with 25-30% glycerol, and where appropriate, with inhibitors,
before flash cooling in a liquid nitrogen stream. X-ray data were collected at 100oK using
a Molecular Structure Corporation (MSC) X-Stream Cryogenic Crystal Cooler System
and an R-Axis IV++ image plate detector with a Rigaku MicroMaxTM–007 X-ray source
equipped with MSC Varimax confocal optics operating at 40 kv and 20 mA. Data were
processed and scaled with D*Trek. Structures were determined via molecular
replacement with AMORE, using pdb entry 1HZP27 as a search model, and refined via
alternating cycles of manual fitting into SigmaA weighted 2mfodfc electron density maps
in COOT84 and computational refinement in CNS71 and Refmac585. Ligand topology and
parameter files used in refinement were generated using the prodrg server.86 Data
collection and refinement statistics are summarized in Table 6.
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Table 6: Data Collection and Refinement Statistic for MtFabh Crystal Structures
2QNZ
2QNY
2QNX
2QO1
Data Collection
Resolution(Å)
Unique Reflections
Redundancy
Rmerge6
Completeness(%)
I/σ(I)
Refinement
Resolution
Number of reflections (work)
Number of reflections (test)
Rwork/Rfree7
Average B(Å2)
DPI(Å)8

2QO0

48.3-2.3 (2.3-2.3)5
31228 (2987)5
12.43 (7.98)5
0.089 (0.206)5
99.3 (96.7)5
19.6 (9.5)5

39.2-2.1 (2.2-2.1)5
35143 (2605)5
3.17 (1.95)5
0.075 (0.150)5
92.2 (69.6)5
10.7 (4.4)5

29.0-2.7 (2.8-2.7)5
19219 (1913)5
3.65 (3.69)5
0.120 (0.264)5
97.3 (98.0)5
8.7 (4.8)5

39.7-2.6 (2.7-2.6)5
20938 (2193)5
2.54 (2.84)5
0.108 (0.244)5
93.2 (98.8)5
7.4 (4.1)5

38.0-1.8 (1.9-1.8)5
46884 (4610)5
6.37 (6.17)5
0.095 (0.314)5
99.8 (99.9)5
11.3 (5.5)5

14.8-2.3 (2.3-2.3)5
27984 (1943)5
3115 (207)5
0.16/0.2 (0.19/0.25)5
28.9
0.212

10.0-2.1 (2.2-2.1)5
31289 (1625)5
3445 (182)5
0.19/0.24 (0.2/0.27)5
30.2
0.213

15.0-2.7 (2.8-2.7)5
17172 (1209)5
1954 (147)5
0.2/0.2 (0.2/0.3)5
26.8
0.352

15.0-2.6 (2.6-2.6)5
18707 (1459)5
2076 (146)5
0.2/0.29 (0.28/0.35)5
40.5
0.389

25.0-1.8 (1.9-1.8)5
42064 (3050)5
4710 (368)5
0.19/0.26 (0.31/0.37)5
22.9
0.162

5

Values in parentheses are for highest resolution shell.

6

Rmerge = ∑ |Ih – ‹I›|/‹I› where Ih refers to the measured intensity for a given reflection and ‹I› refers to the average measured intensity for that reflection.

7

Rwork = ∑ |Fobs – Fcalc|/ ∑Fobs where Fobs and Fcalc refer to the observed and calculated structure factors respectively.

8

DPI = (Natoms/Nobs)1/2c–1/3dminRfree where Natoms is the number of atoms in the refinement, Nobs is the number of reflections, c is the data set completeness expressed as a
fraction, dmin is the resolution and Rfree is the free R factor.
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Deviations from Ideality
Bond Lengths
Bond Angles
Ramachandran Plot
Most Favored (%)
Additional Allowed (%)
Generously Allowed (%)
Forbidden(%)

2QNZ

2QNY

2QNX

2QO1

2QO0

0.007
1.11

0.007
1.08

0.007
1.11

0.007
1.10

0.009
1.22

90.7
9.0
0.2
0.2

90.1
9.1
0.4
0.4

88.1
11.3
0.4
0.2

88.8
10.4
0.5
0.4

90.5
9.0
0.4
0.2

Table 6: Data collection and refinement statistic for mtFabh crystal structures in chapter 5 (continued…).
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5.4 RESULTS
5.4.1 Inhibitor design and activity

Figure 25: Chemical structures of inhibitor ligands used in this study

It has been demonstrated that alkyl-CoA disulfide inhibitors target the active site
cysteine of both ecFabH and mtFabH and that inhibition of these enzymes is specific for
short (C2) or long (C10) alkyl chains respectively, matching their acyl chain substrate
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specificities.83 To investigate the route for ligand binding and reaction with mtFabH, we
synthesized linear inhibitors (Compounds 1-3, Figure 25) composed of two arms linked
by an oxycarbonyl-disulfide group, which can potentially react with the reactive site
Cys112 by acylation or by thiol-disulfide exchange. The arms in the compounds used
here are: ethanol, decyl and decanoic acid. Each pair of arms of a compound is
potentially able to simultaneously bind in the acyl and pantetheinate binding channels of
mtFabH.

Preliminary analysis under standard conditions revealed similar levels of

inhibition for mtFabH (IC50 values: 1, 3.8 ± 0.5 µM; 2, 2.4 ± 0.8 µM; 3, 2.7 ± 0.2 µM).

5.4.2 Characterization of E-I complex:
We initially utilized the “reversibility studies” to analyze the nature of association
between mtFabH and compounds 1-3 and the results are recorded in Appendix 1. The
studies revealed the formation of a covalent adduct, most likely via a disulfide bond,
between the two. We further utilized the “bottoms up” type proteomics approach
(digestion of E-I complex with trypsin followed by HPLC/ tandem MALDI-MS) to
investigate the specific mtFabH residue/s modified on reaction with 1 and 2. Indeed, we
observed the modification at Cys23 residue (on the surface of the mtFabH), but could not
prove the reaction at the active site Cys112 (as proposed), most likely due to the harsh
and long digestion conditions (Appendix 1). We thus diverted our attention to intact
protein ESI-MS techniques to investigate the reaction under relatively milder conditions.
The ESI-MS data complemented with crystal structures revealed the reaction at active
site Cys112 and also threw light on the mode of binding of the inhibitors.
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5.4.3 Electrospray ionization mass spectrometry and crystal structure analysis:
5.4.3.1 Reaction products and crystal structures of mtFabH and C112A mtFabH
with 1
Electrospray ionization mass spectrometry (ESI-MS) was used to follow the
modification of the wild type mtFabH with an excess of 1. Under these conditions the
protein was completely modified (Figure 26b vs 26a and Figure 36a), the two major
species exhibiting mass increases of either 230 or 338 Da. The former of these is
consistent with addition of three 77 Da fragments of A (theoretical increase in mass of
231 Da) to mtFabH monomer, while the latter is consistent with addition of two 77 Da
fragments of A, and one 185 Da fragment of B (theoretical increase in mass of 339).
These analyses indicated that all three solvent accessible cysteines in wild type mtFabH
(the active site Cys112, plus Cys23 and Cys154) can react with 1 through disulfide
exchange and at least one through acylation.
The crystal structure of the inhibition complex of wt mtFabH with 1 showed extra
electron density at the two surface cysteines (Cys23 and Cys154), consistent with
disulfide linked beta-mercaptoethanols, and at the active site Cys112, consistent with
acylation by the long B arm fragment of 1. This crystal structure corresponds to the trimodified reaction product denoted (A + A + B) identified by mass spectroscopy (the
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+ 339 Da (B+A+A)

+ 231 Da (A+A+A)

a

b

Mass (Da)
Figure 26: Reaction products of WT mtFabH with 1. a) Reconstructed ESI-MS spectrum of untreated WT
mtFabH (Control) b) Mass spectrum of WT mtFabH treated with 1. The mass shifts in WT mtFabH on
treatment with 1 is correlated with proposed species (in bracket). WT mtFabH is treated with excess of 1 and
incubated at room temperature for 60 minutes. The mixture is desalted to remove the excess inhibitor and the
species formed are determined using direct infusion ESI-TOF mass spectrometry as determined in material
and methods.
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A + A + A tri-modified species did not crystallize). The contiguous electron density in
both mtFabH subunits extending from the active site Cys112 into both acyl and
pantetheinate binding channels (Figure 27a) was interpreted and refined as dual,
conditional half occupancy of each channel by fragment B of compound 1, whose
carbonyl carbon forms a thioester with the active site Cys112 sidechain –SH.

Figure 27 a: Stereoview of structure around the binding channel of the product complex of compound 1 with
the wild type mtFabH, showing fragment B of its electron density alternately bound in each of the two arms,
the acyl channel (A) and the pantetheinate channel (P), of the substrate binding channel. Contour level of
electron density is 1σ. b). Structure of the A246F mutant with a phenylalanine residue blocking the
pantetheinate channel (gray space filling surface) and fragment B (2 conformations) of compound 1 bound in
the acyl channel.
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The two complexes in the asymmetric unit (one with fragment B in the acyl
channel, the other with B in the pantetheinate channel), both acylated on Cys112, differ
from each other in the interactions they make at the active site. Furthermore, each differs
in detail from its counterpart (with the ligand in the same channel) in the other subunit of
the mtFabH homodimer complex.
The carbonyl group of the complex with fragment B in the acyl channel of one of
the two subunits of the asymmetric unit is oriented toward the oxyanion hole, but does
not make the full complement of hydrogen bonds. The carbonyl oxygen makes a
hydrogen bond to the main chain –NH- of Ala306 but not to the –NH- of Cys112 in
either subunit. In one subunit this oxygen makes a long hydrogen bond to the sidechain
of Ser276. In the other subunit the Ser276 sidechain has alternate conformations, both of
which make favorable (2.6Å) hydrogen bonds to the ester oxygen of the ligand in the acyl
channel. These hydrogen bonds to the Ser276 sidechain –OH may compensate for the
absence of the hydrogen bond to the main chain –NH- of Cys112 in the oxyanion hole.
For the complex with the ligand bound in the pantetheinate channel, the carbonyl
oxygen in one subunit makes a hydrogen bond with the sidechain –NH2 of Asn274 (3 Å),
but not to His244, the two residues that constitute the malonyl anion-binding site. In the
second subunit this oxygen makes tenuously long hydrogen bonds (3.3 Å and 3.6 Å
respectively) to these groups in the malonyl anion site, but makes a favorable hydrogen
bond (2.5 Å) to the sidechain of Ser276 in one of its two alternate conformations.
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+ 153 Da (A+A)

a

b

Mass (Da)
Figure 28: Reaction products of C112A mtFabH with 1. a) Reconstructed ESI mass spectrum of untreated
C112A mutant mtFabH (Control) b) Mass spectrum of C112A mutant mtFabH treated with excess of 1.
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ESI-MS analyses of the C112A mutant complex prepared under the same
conditions showed no tri-modified species (Figure 28 and 36a). Instead, a predominant
di-modified species (mass increase of 152 Da) was observed, consistent with addition of
two 77 Da fragments of A. Two less abundant species (mono- and di-modified),
consistent with the addition of a single B fragment and an A+B respectively, that together
approximated the unmodified species in abundance (Figure 36 a), were also observed.
This decrease in the number of cysteine modifications coincident with mutation of the
active site Cys112 indicates that it is this residue in the wild type mtFabH that can
undergo modification with either fragment A or B.

5.4.3.2. Reaction of A246F mtFabH with 1
The alternate occupancy of the acyl- and pantetheinate channels of wild type
mtFabH by the C10H21OCO groups in the above structures could be realized by two
binding orientations of 1 prior to reaction with the active site Cys112. The alternate
occupancy might also arise if there was only one binding orientation which permitted
reaction with C112, with a subsequent equilibration of the covalently-linked C10H21OCO
chain between the two channels.
In either case, migration of the inhibitor into the pantetheinate channel with
passage through the active site residues into the acyl channel, presents similar formidable
energetic barriers to those facing the natural acyl-CoA substrate, which suggested to us
that there may be alternative modes for substrate and ligand entry to the extended
mtFabH binding site.
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+ 338 Da (B+A+A)

+ 230 Da (A+A+A)

a

+ 154 Da (A+A)

b

Mass (Da)
Figure 29: Reaction products of A246F mtFabH with 1. a) Reconstructed ESI mass spectrum of
untreated A246F mutant mtFabH (Control) b) Mass spectrum of A246F mutant mtFabH treated with
excess of 1.
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To test this hypothesis we created an A246F mutant mtFabH, which introduces a
large obstructive group into the pantetheinate channel about 8 – 9Å out from the active
site Cys112. This A246F mtFabH mutant had no detectable catalytic activity in an
elongation assay with lauroyl-CoA and malonyl-ACP. Mass spectrometry (Figures 29
and 36a) revealed that an incubation of 1 with this A246F mutant resulted in the same trimodification seen with the wild type enzyme. Both tri-modified species (A + A + A) and
(A + A + B) were observed, with an apparent greater abundance of the latter.
The crystal structure of the unliganded A246F mutant showed no significant
differences in structure relative to the wild type except for the presence of the bulky
phenylalanine, which clearly blocks access to the active site cysteine via the
pantetheinate channel. Electron density was observed in the acyl channel that can be fit
with a free laurate (not linked to the active site cysteine). Like other mtFabH structures
crystallized in the absence of ligands, including the wild type, the electron density in the
acyl channel that can be fit with a free laurate is probably taken up during expression and
purification of the recombinant mtFabH.
The co-crystal structure of A246F mtFabH with 1 (Figure 27b) shows the overall
structure of the protein to be virtually identical to the unliganded mutant.

The

hydrophobic ligand, modeled as laurate in the acyl binding channel of the unliganded
A246F crystal structure, is replaced in the liganded form by electron density contiguous
with Cys112 that can be well fit by fragment B of 1 in thioester linkage with Cys112
(Figure 27b). There was no ligand electron density in the blocked pantetheinate channel.
In contrast to fragment B in the acyl channel of wt mtFabH, the carbonyl group of B in
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the A246F mtFabH complex assumes two alternate orientations, one toward the oxyanion
hole and the other toward the malonyl anion binding site. In one subunit, the carbonyl
oxygen makes hydrogen bonds with optimal stereochemistry to –NH- of Cys112 and
Ala306 in the oxyanion hole of the acyl- binding site, while in the other subunit the
hydrogen bond to –NH- of Cys112 is too long to be significant. In both subunits of the
dimer, the alternative conformation of the carbonyl oriented toward the malonyl anion
binding site positions the oxygen at long hydrogen bond distance from the His244 and
Asn274 proton donors.
The vacant pantetheinate channel in the A246F mutant confirms that this channel
is blocked by the phenylalanine mutation and indicates that 1 must enter the acyl binding
channel by a path other than the pantetheinate channel.

We hypothesize that this

alternative path exists in an ‘open’ form of the enzyme in which the extended binding site
consisting of the two channels is accessible to ingress of the inhibitor as a result of the
lifting of a loop that covers both binding channels (see Discussion below).

5.4.3.3 Reaction of mtFabH, C112A mtFabH and A246F mtFabH with 2 and 3
Inhibitor 1 contains only one long hydrophobic arm, which as shown above can
occupy either channel of wt mtFabH, or just the acyl binding channel of the A246F
mutant. To probe how inhibitors with two hydrophobic arms, in principle competent to
bind both channels, would react with the A246F mutant, we synthesized 2 and 3, both
with two long arms differing only in the addition of a carboxylate group to the C10 alkane
chain. In addition to providing potential full occupancy of both channels of the enzyme,
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the anionic carboxylate of 2 and 3 was expected to both inhibit the putative transit of the
long chain through the pantetheinate channel and into the acyl channel and to direct
ligand orientation according to the relative hydrophobicities of the two arms and the two
arms of the binding channel.
The reaction of wt mtFabH with 2 (Figures 30 and 36b) resulted in two trimodified products with mass increases of either 617 Da or 648 Da. The former is
consistent with addition of two 217 Da A’ fragments and one 185 Da B’ fragment and the
latter to addition of three 217 Da A’ fragments (an overall increase in theoretical mass of
619 Da or 651 Da respectively) per mtFabH monomer. There was no detectable
unmodified protein. Reaction of 3 with wt mtFabH gave predominantly the tri-modified
products exclusively with A” chain fragment (some A” + A” di-modified species was
also observed).
Crystal structures of the wild type enzyme with 2 and 3 showed that in both cases
a disulfide species was formed between the A’ or A” fragments and the active site
Cys112 (Figures 37a and 37 b respectively). In the structure of mtFabH with 2, the
undecanoic

acid

group

surprisingly

is

in

the

acyl

channel

and

the

O-

undecylcarbonothioate lies in the pantetheinate channel, detached from the C112disulfide-linked undecanoic acid, and with its carbonyl oxygen oriented towards the
malonyl anion binding site of His244 and Asn274 (Figure 37a). Hydrogen bonds in this
binding site are close to optimal in one subunit (2.72Å and 2.74Å), but are long in the
other subunit (3.34Å and 3.45Å). The crystal structure of wild type mtFabH complexed
with 3 (Figure 37b) shows the decyl
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+ 648 Da (A’+A’+A’)

+ 618 Da (B’+A’+A’)

a

b

Mass (Da)
Figure 30: Reaction products of WT mtFabH with 2. a) Reconstructed ESI mass spectrum of untreated WT
mtFabH (Control) b) Mass spectrum of WT mtFabH treated with excess of 2.

102

+ 433 Da (A’+A’)

+ 215 Da (A’)

a

b

Mass (Da)
Figure 31: Reaction products of C112A mtFabH with 2. a) Reconstructed ESI mass spectrum of untreated
C112A mutant mtFabH (Control) b) Mass spectrum of C112A mutant mtFabH treated with excess of 2.
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a

b

Mass (Da)
Figure 32: Reaction products of A246F mtFabH with 2. a) Reconstructed ESI mass spectrum of untreated A246F
mutant mtFabH (Control) b) Mass spectrum of A246F mutant mtFabH treated with excess of 2.
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+520 Da (A”+A”+A”)

+348 Da (A”+A”)

+175 Da (A”)

a

b

Mass (Da)
Figure 33: Reaction products of WT mtFabH with 3. a) Reconstructed ESI mass spectrum of untreated WT
mtFabH (Control) b) Mass spectrum of WT mtFabH treated with excess of 3.
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+ 345 Da (A”+A”))

a

+ 173 Da (A”)

b

Mass (Da)
Figure 34: Reaction products of C112A mtFabH with 3. a) Reconstructed ESI mass spectrum of untreated C112A
mutant mtFabH (Control) b) Mass spectrum of C112A mutant mtFabH treated with excess of 3.
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+ 174 Da (A”)

a
+ 349 Da (A”+A”)

b

Mass (Da)
Figure 35: Reaction products of A246F mtFabH with 3. a) Reconstructed ESI mass spectrum of untreated
A246F mutant mtFabH (Control) b) Mass spectrum of A246F mutant mtFabH treated with excess of 3.
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chain

in

the

acyl

channel

disulfide

linked

to

Cys112.

The

O-

carboxyundecylcarbonothioate in the pantetheinate channel is present in the same
orientation as the O-undecylcarbonothioate group in the complex with 2 with its
carboxylate at the mouth of the pantetheinate channel and its carbonyl oriented toward
the malonyl anion binding site, but too far from His244 and Asn274 in both subunits to
make hydrogen bonds. This latter difference vis a vis the complex with 2 may be a
consequence of lattice interactions of the carboxylate that are transmitted to the other end
of the chain in the malonyl anion binding site.
These observations demonstrate that the linkage positions of the undecanoic acid
chain and the decyl chain in 2 and 3 do not determine the orientation of binding these
compounds in the acyl site of mtFabH. For 2 the binding of the undecanoic acid in the
acyl binding channel is possibly stabilized by the presence of the Arg2024 side chain at
the top of the acyl channel in both subunits (4 – 5Å from the carboxylate). In one
subunit, there is also a hydrogen bond between one of the carboxylate oxygens (inferred
to be in the protonated state) and the amido oxygen of the side chain of Gln191. The
recurrence of disulfide exchange products in both cases where the inhibitor has two long
arms suggests that orientation in binding is determined primarily by the positioning of the
oxycarbonyl-disulfide group in the active site. The crystal structures show that the
carbonyl oxygen of this group is directed toward the malonyl anion binding site, and this
may be the principal determinant of ligand orientation. For a mechanism involving transit
through the pantetheinate into the acyl channel, there is no obvious basis for
discrimination in the orientation of the oxycarbonyl-disulfide group. This and the
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Figure 36: ESI-MS analyses of products of the reactions of compounds 1 (a), 2, (b), and 3 (c) with
the wild type, C112A, and A246F mtFabH. Arrows indicate species for which a crystal structure was
obtained.
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presence of the carboxylate in the acyl channel argue against a threaded transit of the
ligand into its final reactive position and for a lower energy pathway of entry.
Reaction of 2 and 3 with the C112A and A246F mutants leads to no detectable trimodification of the protein (Figures 31, 32, 34, 35, and 36 b and c). For both inhibitors 2
and 3, a major reaction product species was the unmodified mutated proteins. These
results contrast with those of the wild type FabH where there was no unmodified protein
and the major species observed with either inhibitor was the tri-modified species. A
striking observation from these ESI-MS studies is that the A246F mutant behaves like the
C112A mutant with 2 and 3, but like the wild type mtFabH with 1. The presence of the
phenylalanine mutation dramatically affects reaction of the active site cysteine, but only
with inhibitors having two long chain hydrophobic arms.
A co-crystallization of 3 with the A246F mutant revealed a complex with the A”
fragment linked by a disulfide to Cys112 and lying in the acyl channel like the ligand
complexes with wt mtFabH (Figure 37c). Fragment B”, which is observed in the
pantetheinate channel of wt mtFabH, is absent in this A246F mutant and this channel
remains blocked by the phenylalanine mutation (Figure 37c). Thus, while the ESI-MS
results indicate that efficient reaction of the active site cysteine with 3 is affected by this
mutation, the crystallization studies indicate that the reaction occurs. Formation of this
product by entry of 3 through the pantetheinate channel, which is blocked, seems
unlikely. The most parsimonious hypothesis for its formation is that 3 binds to an ‘open’
form of the enzyme through interaction of its oxycarbonyl-disulfide group at the malonyl
anion binding site; this orients A” in the acyl channel for disulfide exchange with
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Fig. 37
a

b

c

Figure 37. a. Structure of the product of compound 2 with mtFabH showing fragment A’ in the acyl channel disulfide linked to Cys112,
and fragment B’ in the pantetheinate channel. Arrows from A and P point to acyl channel and pantetheinate channel.
b. Structure of the product of compound 3 with wt mtFabH showing fragment A” in the acyl channel disulfide linked to Cys112 and
fragment B” in the pantetheinate channel.
c. Structure of the product complex of compound 3 with A246F mtFabH showing fragment A” in the acyl channel disulfide linked to
C112. The surface shape of the empty pentetheinate channel is shown blocked by F246.
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Cys112, while B” extends into solvent from the ‘open’ form in lieu of binding in the
pantetheinate channel, and dissociates when the thiol-disulfide exchange reaction occurs.

5.5 Discussion:
5.5.1 Unresolved aspects of M. tuberculosis FAS II enzyme mechanisms:
The M. tuberculosis type II FAS pathway for synthesis of long chain (>C54) fatty
acid precursors of the mycolic acid component of the bacterial cell wall
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is a proven

target for existing Tb treatments and offers other opportunities for development of new
treatments.

Binding and transfer of long chain acyl reactants and products almost

certainly require enzyme conformational changes and specific protein-protein
interactions, some of which may be vulnerable points for therapeutic development. In
particular, it is not clear how some well characterized enzymes of this pathway can
accommodate substrates of widely variable acyl chain length and how the protein
components of the pathway interact.
Characterization and structure determination of individual enzymes37,88-91 and
acyl-carrier protein in this pathway92 provide evidence that conformational changes of the
proteins play an important role in some individual steps. For instance, conformational
changes on substrate binding to InhA (FabI) provide an accessible acyl binding crevice to
which a C16 thioester binds in a U-shaped conformation.93 For the reductive enzyme βketoacyl reductase (MabA), an open and closed form of the enzyme have been observed
and docking studies suggest that an L-shaped binding pocket in the open form can
accommodate substrates up to C16,89 but it is unclear how physiological substrates with
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acyl chains longer than C16 bind to either InhA or MabA. An acyl binding region for C10
and C12 substrates in the condensing enzyme mtKasB has been identified and is Ushaped. While this binding pocket is larger and more occluded than the corresponding
binding region of the E. coli FabB (which catalyzes the analogous reaction during
palmitate biosynthesis in this microorganism),91 there is no data suggesting how the much
longer physiological substrates bind to mtKasB.
There is less information on protein-protein interactions both in the M.
tuberculosis type II FAS and also with type I FAS, but there is evidence that such
interactions are essential for mycobacterial viability.94,95 Formation of a type II FAS
complex, possibly with some features resembling those in the type I FAS,96-98 is likely
required to facilitate passage of the extremely long chain fatty acid substrates between
enzymes.
To date there is no information on conformational changes or protein-protein
interactions of mtFabH. The linear acyl binding pocket appears to be capable of accepting
substrates only up to about C16 in length, (chapter 3) while experiments have shown that
the enzyme can process C22 substrates.57 The crystal structure of mtFabH also raises the
question of how substrate (and product) enter (and leave) the extended L-shaped binding
site consisting of two long, tandem channels, which are roughly perpendicular to each
other. The distal, buried acyl-binding channel in the mtFabH structure appears accessible
only through the pantetheinate channel, which opens to solvent. However, a binding
process in which lauroyl- or other long chain acyl-CoA is threaded first through the
pantetheinate channel into the acyl channel seems implausible.
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5.5.2 A model for substrate binding and product release in mtFabH
An alternative to this substrate-threading model is a mechanism in which mtFabH
exists in an ‘open’ conformational state, where both the acyl and pantetheinate binding
channels are accessible. To test this hypothesis, we used active-site directed oxycarbonyldisulfide inhibitor ligands flanked on each side by alkyl or carboxyalkyl chains.
Since existing crystal structures of both liganded and unliganded mtFabH are
inferred to be in the ‘closed’ conformational state of the enzyme, we combined solution
ESI-MS and crystal structure data to analyze the reaction pathways and product
complexes of these inhibitor ligands with mtFabH. These results provide evidence that
these compounds do not bind to mtFabH by passage through the pantetheinate channel
into the acyl channel. Inhibitor 1 efficiently enters the acyl-channel of the mtFabH A246F
mutant, blocked in the pantetheinate channel, and the carboxylated C10 arm of compound
2 binds in the acyl channel of wt mtFabH despite the inferred energetic obstacle to
migration of a charged (or possibly protonated) group through two hydrophobic channels.
These data argue strongly for an ‘open’ form of mtFabH that binds acyl substrates or
inhibitors in a single step.
A crystal structure of a disordered ecFabH63and recent kinetic data for inhibition
of this enzyme with alkyl-CoA disulfide inhibitors83 support a model in which ‘open’
dimeric protein becomes ordered on binding of an acetyl-CoA substrate or methyl-CoA
disulfide inhibitor. For the mtFabH there is no experimental crystal structure in a
disordered or ‘open’ form, and a large structural change in the observed ‘closed’ crystal
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Figure 16

Figure 38: (a) Backbone ribbon model of the dimeric C112A mtFabH complex with lauroyl-CoA
(color-coded space filling) bound in active sites of both monomers. The putative flap that covers the
extended L-shaped binding site is colored gold (front) in the right-hand (gray) monomer and magenta
(back) in the left-hand (blue) monomer subunit.
(b) Surface figure of dimer in Figure 6a rotated approximately 90° about the horizontal axis
showing the two flap covers (gold) of each of the two binding sites (defined by lauroyl-CoA (color
coded space filling). The flap in the blue left monomer is in the ‘closed’ conformation, thereby burying
the lauroyl-CoA ligand; the flap in the gray right monomer is in the ‘open’ conformation (movement
shown by arrow), opening the lauroyl-CoA binding site to solvent.
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structure would be required to provide direct access to the long hydrophobic acyl
channel. Inspection of the mtFabH structure reveals how the extended binding site of this
enzyme could be exposed for concerted binding of long chain acyl-CoA substrates. A
single polypeptide segment (residues 183 – 209, ecFabH numbering) forms most of the
top of the acyl channel and part of the top of the pantetheinate channel in mtFabH (Figure
38a). We note that this flap includes an insertion sequence in mtFabH relative to ecFabH
that mediates intersubunit interactions in the mtFabH dimer. The extremities of this
polypeptide segment coincide with glycine residues (181 and 207) that are almost
completely conserved across 5 FabH sequences. Synchronized hinge motions at each of
these glycines could raise this polypeptide flap to expose most of the substrate binding
site of mtFabH to solvent and to the binding of substrates and ligands (Figure 38b).
This proposed ‘open’ conformation of mtFabH provides an understanding of how
both acyl-CoA substrates and the ligands 1-3 bind and react with the wild type enzyme
and how 1 reacts with the A246F mutant. The proposed ‘open’ conformation of the
mtFabH also offers a solution to the dilemma of how mtFabH utilizes substrates longer
than palmitoyl-CoA (the maximum permitted chain length suggested by the ‘closed’
mtFabH structure). Exposure of the acyl binding channel would allow longer chains to
extend outward from the channel, possibly interacting with the exposed hydrophobic
underside of the opened flap in a modified ’closed’ conformation of mtFabH that is
necessarily slightly different from that observed with lauroyl-CoA substrate (chapter 3).
We propose that ordering or closing of the mtFabH on the substrate or inhibitor is
required for efficient reaction with the active site cysteine and that this is why 2 and 3
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react poorly with the A246F mutant. Reaction of this mutant with 3 results in loss of
fragment B” whose only plausible position during this reaction is extended outward from
the binding site, since the pantetheinate channel is blocked.
In this model for acyl-CoA binding to mtFabH, the acyl-CoA reactants
synchronously bind both arms of the substrate binding site and CoA product is released
from the mouth of the pantetheinate channel in the first stage of the reaction. In the
second stage of the mtFabH reaction these different paths for substrate binding and
product release would be reversed: the phosphopantetheine arm of ACP carrying the
malonyl thioester would enter the mouth of the closed pantetheinate channel after CoA
dissociation, and following decarboxylative condensation of malonyl-ACP, transition
back to the ‘open’ form of the enzyme would permit egress of the hydrophobic 3ketoacyl ACP product.

This open form could also facilitate transfer of the long,

hydrophobic acyl chain from the acyl channel binding site of mtFabH to a putative
binding site on ACP. This latter step is supported by kinetic analyses of the complete
mtFabH reaction that indicate an apparent difference in acyl group specificity when using
E. coli vs M. tuberculosis ACP (ACPM),57 and by the structure of butyryl-ACP in which
the acyl group is sequestered in a site on the ACP.99 We have observed ACP-dependant
changes in substrate specificities of other FabH enzymes and kinetic data for inhibition of
ecFabH on binding a MeSSCoA inhibitor are consistent with conformational transitions
on malonyl-ACP binding.83
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5.6 Conclusions
In conclusion, the work described here demonstrates that large scale dynamic
motions in mtFabH are likely required for ligand binding. Such conformational changes
may be critical for the synchronization of binding and dissociation steps, not only in
mtFabH but also in other enzymes of the FAS pathways, including transfers between the
FASI and FASII components. They require consideration and may also offer alternative
approaches in developing new therapeutics that target mycolic acid biosynthesis.
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6. CHARACTERIZATION OF NAPHTHALENE-BASED COMPOUNDS AS
NOVEL INHIBITORS OF FabH

6.1 Summary
A naphthalene based compound (A) (Figure 39) was previously identified as an
effective inhibitor of pfFabH in a screening program at WRAIR (Walter Reed Army
Research Institute). A number of structure based analogs were synthesized and found to
be effective against purified pfFabH with IC50 values in the range of 0.027 µM to >500
µM (unpublished data). In this study, we have tested these analogs against FabH from M.
tuberculosis and reported a similar SAR with IC50 values ranging from 0.6 µM to 138
µM. A comparison of the two sets of IC50 values was utilized to deduce a preliminary
pharmacophore for this series of inhibitors.

6.2 Introduction
The emergence of multidrug resistance in recent times has shifted the impetus of
anti-microbial research from lead discovery towards target discovery. β-ketoacyl-ACP
synthase (FabH) is one such enzyme which, owing to its key role in type II fatty acid
synthesis, has recently attracted considerable attention as a good anti-microbial drug
target. Consequently, it has been characterized from a number of species including highly
pathogenic microbes such as M. tuberculosis27,57,88,100 and S. pneumonia.101 Further, the

119

availability of crystal structures from various species has added enormously to the
mechanistic knowledge of this enzyme and various research groups have directed
significant efforts towards the design of selective FabH inhibitors in the recent past.
Daines et al.102 utilized a combination of high throughput screening and homology
modeling to identify a series of indole-based inhibitors found to be active against spFabH
and ecFabH. These inhibitors were shown to bind non-covalently in the CoA/malonylACP pocket close to the active site triad. A computational search of National Cancer
Institute (NCI) database for compounds structurally similar to thiolactomycin resulted in
identification of several 1,2-dithiole-3-ones as potent inhibitors of both E. coli FabH and
S. aureus FabH.81,103 In contrast to the indole-based FabH inhibitors the mode of binding
of these inhibitors could not be determined. Recently, Nie et al. have used a structurebased drug design approach which afforded a series of benzoylaminobenzoic acid
compounds as potent inhibitors of E.

faecalis FabH.58 Some of these compounds

demonstrated good antibacterial activity against Gram-positive and some Gram-negative
organisms.
Here we have explored the inhibitory activity of a series of naphthalene-based
compounds, which were found effective against pfFabH and ecFabH (unpublished data),
on mtFabH. The lead compound “A” (Figure 39) was initially identified in a screening
effort by Division of Experimental Therapeutics branch of Walter Reed Army Institute of
Research (WRAIR) for inhibitors of the P. falciparum FabH. This was later found to be
active against FabH from E. coli and M. tuberculosis which led to the synthesis of
fourteen analogs of inhibitor A (series 1-4; synthesis was carried out by Dr.
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Alhamedsheh). These compounds were tested against purified pfFabH enzyme and the
IC50 values are listed in Table 7 (pfFabH IC50 column). The compounds were also tested
against chloroquine (CQ)- sensitive (D6) P. falciparum strain (pf D6 IC50 column). In this
study, we have tested these compounds against purified mtFabH (mtFabH IC50 column)
and deduced a generalized SAR based on IC50 values from the two FabHs.

Figure 39: Structure of the lead compound A. The rings are labeled as discussed in the text.

6.3 Results and Discussion
The series of analogs 1-4 (see table 7) were tested against purified M. tuberculosis
FabH using the ACPM independent assay described in chapter 2 and the IC50 values are
listed in table 7 along with IC50 values for P. falciparum FabH and in-vivo inhibitory
activity against chloroquine (CQ)- sensitive (D6) P. falciparum strain for comparison (pf
D6 IC50 values).
We initiated our SAR analysis with the variation of the ‘A’ ring. Removal of the
methyl group from ring ‘A’ of our lead compound 1a led to ~ 4 times decrease in
inhibitory activity in compound 1b in mtFabH. Further substitution of the methyl group
to larger propyl and chloro groups and much bulkier phenyl group (compounds 1c, 1d
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and 1g respectively) resulted in ~2-5 times decrease in inhibitory activity in mtFabH.
Replacement of methyl to amine (1e) resulted in prominent 50-fold decrease in inhibitory
activity in mtFabH while the relatively bulkier acetamide substitution (1f) had a meager
effect on the activity. Total removal of ‘A’ ring of the lead compound 1a to 1h led to a
small decrease in inhibitory activity indicating the non-essential nature of the ‘A’ ring. A
very similar pattern in IC50 values on varying the ring “A” was noted for pfFabH
enzymes with series 1.
The SAR analysis of the ring “B” of the lead compound 1a was concentrated
mainly on the importance of 1, 4 di-hydroxyls. Removal of the two hydroxyls (1j)
resulted in > 200 fold decrease in inhibitory activity against mtFabH with an IC50 value
of 138 µM. The oxidation of di-hydroxyls to di-keto groups (2a) resulted in a slight
decrease in inhibitory activity but not nearly as drastic as their removal. We noticed a ~ 5
times decrease in inhibitory activity on mtFabH and a ~ 20 fold decrease in inhibitory
activity against pfFabH for compound 2a. Lastly, we tried the variation of the ‘C’ ring by
removing the ‘C’ ring of compound 1a and 1f to 3a and 3b respectively. A complete loss
of inhibitory activity against pfFabH enzyme and parallel 50-fold decrease in mtFabH
IC50 values strongly suggested the necessity of ring ‘C’. Substitution of naphthalene-1,4diol (1a) to anthracene-1,4-diol (4a) resulted in a ~ 10 fold decrease in activity indicating
the steric limit on ring ‘C’.
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OH

Table 7: IC50 values of compounds 1-4 against pfFabH and mtFabH. The mtFabH IC50
values determined in this study are highlighted.
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The preliminary inhibitory analysis showed a clear similarity between the
inhibitions of two FabHs by this series of compounds. The summary of SAR based on the
above analysis is as follows. A wide range of substitution as well as the complete
removal was well tolerated on ring ‘A’, which strongly suggests a large flexibility of this
part of molecule. The di-hydroxyl groups on the ring ‘B’ are required for activity but can
be replaced with di-keto groups too. The Ring ‘C’ was noted to be absolutely essential for
activity as its absence led to drastic decrease in inhibitory activity in both enzymes.
Finally, in-vivo activity was also tested in chloroquine (CQ)- sensitive (D6) P.
falciparum strain and the results are shown in table 7. The “ineffective” in-vitro inhibitors
(series 3 and 1j) showed comparable inhibition level (14 –75 µM) to the “effective” invitro inhibitors (1a, 1c, 1h). The absence of any co-relation between the in-vivo and invitro values strongly suggests that FabH is certainly not the sole enzyme target for this
class of inhibitors.

6.3.1 Mode of binding
The available structural data depicts two distinct channels for ligand binding in all
FabHs. The first channel, leading up to the active site Cys112 is shown to accommodate
the pantetheinate arm of both CoA and ACP. The second channel, located at the distal
end of the active site cysteine is shown to accommodate the variable acyl chain of the
first substrate acyl-CoA. mtFabH contains the largest acyl pocket in FabH class of
enzyme and consequently it can catalyze the condensation of the long acyl-CoAs (C6-C20
CoAs) with malonyl-ACP to form the β-ketoacyl-ACP product. The inhibition pattern of
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this series of compounds tested on mtFabH and pfFabH enzymes strongly indicates that
these inhibitors would most likely bind in the common CoA/malonyl-ACP pocket
considering the large difference in size of acyl pockets in two enzymes. Unfortunately,
despite several co-crystallization attempts we were not able to determine the absolute
mode of binding of these compounds in mtFabH enzyme. In addition, docking of the
most potent analogs resulted in unconvincing results. Further biochemical studies such as
mutational analysis are required to elucidate the mode of binding.

6.4 Conclusions
A novel class of naphthalene based compounds is tested against clinically
important mtFabH enzyme and the IC50 values were compared with pfFabH IC50.
Although the inhibitory activity of the analogs based on the lead compound did not
improve much, a basic pharmacophore was established based on available data. This
pharmacophore can be further utilized to search for related structures in the vast chemical
libraries available and also can be further improved by conventional chemical synthesis
and QSAR technique.

125

7. Conclusions and Future directions

1. M. tuberculosis FabH (mtFabH) is claimed to be a key enzyme for its proposed
regulatory role in the biosynthesis of mycolic acid, an essential component of the
mycobacterial cell wall responsible for imparting rigidity and virulence to the
bacterium. The methods to assay mtFabH, thus far, have been very tedious and
costly due to technical difficulties associated with physical separation of its
substrate from its product. We have designed a simpler and more cost efficient
assay in this study.
This assay utilizes malonyl-CoA instead of malonyl-ACP and thus is the first
ACP independent assay designed for mtFabH. We propose to utilize this assay in
conjunction with the analogous malonyl-ACP-dependent mtFabH assay to
investigate the molecular interaction between the mycobacterial acyl carrier
protein (ACPM) and mtFabH. This study will involve mtFabH mutants mutated at
key amino acid residues that are likely to be involved in interaction with ACPM.
The relative condensation activity in ACP-dependent versus our ACPindependent assay can help us understand the role of those residues in their
interaction with ACPM.
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2. Fatty acid enzymes in M. tuberculosis are responsible for synthesizing the long
acyl chain component of the mycolic acids. Although mycobacterium enzymes
share functional and structural similarities with FAS enzymes from other species,
they have structural features, which make them unique. mtFabH is known to
process much longer acyl-CoA substrates than its analogous enzymes in other
bacterial species. In this study we solved the crystal structure of mtFabH with its
substrate dodecanoyl-CoA. We observed that there is room for no more than four
more carbons (maximum of hexa-decanoyl CoA) in the acyl pocket, which does
not agree with its physiological substrate specificity. Although a possible
hypothesis to resolve this paradox is set forth in chapter 5, a stable crystal
structure of mtFabH complexed with C18-C24 CoA would be helpful in
understanding the molecular dynamics involved in long acyl chain binding in the
acyl pocket of mtFabH. In our previous attempts to obtain a co-crystal of mtFabH
with tetradecanoyl-CoA or hexadecanoyl-CoA, we observed that a small impurity
of dodecanoyl CoA in the preparation resulted in crystallization of density
corresponding to doecanoyl CoA in the acyl pocket. We propose to achieve a pure
preparation of longer acyl-CoAs (C18-C24 CoA) using the HPLC technique, and
use it to prepare stable co-crystals with mtFabH. This will help us greatly in
understanding the dynamics of substrate binding and possibly also the ligand
trafficking in mtFabH.
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3. Fatty acid biosynthesis (FAS) has been recently identified as an excellent drug
target for bacteria in the wake of rising drug resistance. Although some clinically
and commercially available compounds (eg isoniazid, triclosan) do target FAS,
the full aptitude of this system is not yet utilized as many enzymes with no
inhibitors in the clinical pipeline are likely to be good targets. FabH is one such
enzyme with a proposed regulatory role in fatty acid biosynthesis in bacteria.
While FabH from bacterial species such as E. coli is important for investigational
purposes, FabH from clinical species such as M. tuberculosis and H.pylori hold
more promise clinically. With only a handful of drugs that are effective against
TB, and with the rise of MDR, it is imperative to develop new effective TB drugs.
We plan to fully characterize mtFabH using the ACP dependent and ACP
independent assay to have better understanding of the enzyme, which further can
aid in discovery of novel anti-tubercular drugs.

4. The ligand trafficking in mtFabH is one of the many unanswered questions which
are critical to understanding the physiological functioning of this enzyme at the
molecular level. In this study, we attempted to answer this question using a series
of oxycarbonyl-disulfide ligands and a “CoA channel blocked” mtFabH mutant.
We developed the first ever proof for mtFabH that large scale dynamic motion is
important for its catalytic functioning. Further, we proposed a likely portal for
substrate entry and product exit in mtFabH. This proposed flap formed by a single
polypeptide segment (residues 183 – 209, ecFabH numbering) could expose most
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of the acyl and CoA channels, thus serving as an entry and exit portal for
substrate/product. We plan to investigate the proposed role of this polypeptide
flap using a combination of mutational and other biochemical tools. An analysis
of a series of mtFabH mutations at the hinge residues of this proposed flap -- for
example, mutating the conserved glycine residues to more restrictive and bulkier
residues like alanine or proline - should help us understand the role of these
residues.

5. In a previous study by Besra et al57, it has been observed that, under the
experimental conditions used, the extent of acylation is found to be less than 25
%. Further, the rate of acylation is surprisingly slower than the overall
condensation rate of mtfabH. These results indicated a possible in-equivalency
between the two monomers of the mtFabH dimer. In this study, we have shown
for the first time that both mtFabH monomers can be fully acylated or alkylated
by a mixture of acyl-CoA or alkyl-CoA disulfide. Surprisingly, ESI-MS studies
showed that only dodecanoyl-CoA reacted with mtFabH from a mix of C6-C20 CoAs. This observation is in concordance with a previous one57 where longer
substrates are processed more efficiently when cognate ACPM was utilized.
These observations suggest a possible role of ACPM in priming of substrates
and/or off-loading of products from mtFabH. We propose to investigate this
particular aspect of mtFabH functioning using a variety of biochemical techniques
including mutagenesis and mass spectrometry.
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6. The assay developed in this study (chapter 2) was used to test a series of
naphthalene based compounds which were identified in a library screening effort
by Walter Reed Research Institute (chapter 6). This assay was also used to test a
series of compounds which were found effective against ecFabH.104 The
commercial availability of all the components of our assay and its simplicity
makes it much more efficient to screen numerous potential inhibitors at one time
without prior preparation of substrates and with minimal expenditure. We plan to
further utilize our assay to speed the discovery and development of novel
inhibitors of mtFabH as potential anti-tubercular agents.
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Appendix 1
A.1 Results
A.1.1 Characterization of the E-I complex:
A.1.1.1 Probing the nature of association between mtFabH and Inhibitors 1-3:
We utilized a simple reversibility test to investigate the nature of association
(covalent vs. non-covalent) between mtFabH and the inhibitors 1-3 (Figure X1). The
enzyme was pre-incubated with excess of inhibitor at 37 ˚C for 60 minutes and the
activity of this inhibited enzyme is checked using the standard assay to confirm the
formation of E-I complex (> 95% inhibition; Figure X1 - “E~I complex” column). The
control experiment is set up with untreated mtFabH under similar conditions. The
100
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% mtFabH Activity
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Figure X1: Probing the nature of association between mtFabH and I - The effect of dialysis and
DTT treatment on condensation activity of mtFabH treated with inhibitor 1 (blue bars), 2 (maroon bars)
or 3 (beige bars).
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complex is then subjected to multiple dilution-concentration steps (a 1000 fold dilution
factor is achieved as described in methods) to remove any excess or readily dissociable
inhibitor from the enzyme and the residual enzymatic activity is indicative of reversibility
of E-I complex. A non-covalent reversible E-I complex under these conditions would
dissociate easily and the resultant freed enzyme would show restoration of activity while
on the other hand, a covalently bound mtFabH in E~I complex would still show inhibited
enzymatic activity. The experimental data showed that inhibitor treated mtFabH on
dilution shows 1-2 % enzymatic activity (compared to Control; Figure above – “E~I –
Dialysis” column) with all three inhibitors and thus suggested a non-reversible complex
formation. This complex when treated with excess DTT (and subsequently dialyzed)
resulted in restoration of 60-90% of activity compared to mtFabH control (Figure above “E~I - DTT treatment” column; DTT treatment of mtFabH~Inhibitor 1, 2 and 3 showed
59.9 %, 67.95 % and 85.65 % restoration of activity respectively) suggesting the
formation of a disulfide linkage between mtFabH and the inhibitor series. Mass
spectrometry and X-ray crystallographic studies as discussed in chapter 5 confirmed the
formation of this disulfide linkage between the mtFabH cysteines and the inhibitor and
also showed the exact nature of the complex formed.
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A.1.1.2 Identification of the site of modification:
To investigate the precise site of modification, we performed limited proteolysis
of mtFabH - Inhibitor complex by trypsin followed by Reverse Phase-HPLC (RP-HPLC)
fractionation of the resultant peptides to look for any modified peptide peaks. The control
experiment consisted of untreated mtFabH digested in parallel under identical set of
conditions. The modification of mtFabH peptide with the inhibitor would most likely
alter its hydrophobicity and thus an appearance of new peptide peak or movement of
existing one on the C18 matrix could implicate the modified peptide fragment. This
peptide fragment could then be characterized to conclusively identify the nature and site
of the modification.

A.1.1.2.1 Standardization of Digestion conditions:
We first started with the optimization of various digestion and HPLC conditions
to ensure sensitivity and reproducibility in each run. The UV traces of undigested WT
mtFabH and inhibitors (Control reactions) are shown in Figure X2. It was evident from
the HPLC traces that the inhibitors bound tenaciously to the C18 column matrix and
eluted at 100 % acetonitrile concentration (Figure X2b and X2c). The maximum
concentration of acetonitrile required to elute all peptide fragments was found to be ~
60% and thus after a few HPLC runs 100 % acetonitrile was used to wash the column to
ensure reproducibility. Other variables such as the amount of trypsin, time of digestion
and the digestion conditions were also optimized and the results are shown in Figures X3,
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X4 and X5. Based on the peptide profiles (HPLC traces), the digestion reaction was set to
run under native conditions with 1:20 w/w of mtFabH / trypsin for 11 hrs as described in
materials and methods. The digestion reaction was not run for extended period of time to
preserve any labile association between mtFabH and inhibitors. Also, Dehydroascorbic
acid was added to maintain the oxidizing conditions to maintain disulfide bonds.
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a

b

c

Figure X2: Standardization of digestion conditions – Control reactions- RP-HPLC traces of a)
undigested WT mtFabH, b) WT mtFabH + Inhibitor 1 and c) WT mtFabH + Inhibitor 2. The conditions
used are described in the methods section. The UV detection wavelength is set at 204 nm.
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a

b

Figure X3: Standardization of digestion conditions- trypsin / mtFabH ratio: RP-HPLC analysis of
the peptide mixture obtained from trypsinolysis of WT mtFabH performed at a) 1 : 60 trypsin / mtFabH
ratio and b) 1 : 20 trypsin / mtFabH ratio.

a

b

Figure X4: Standardization of digestion conditions- Native vs Denatured: RP-HPLC analysis of peptide
mixture obtained from trypsinolysis of WT mtFabH performed under a) Denaturing conditions with
guanidium chloride and b) native conditions.
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Min
Figure X5: Standardization of digestion conditions -time of digestion: RP-HPLC analysis of peptide
mixture obtained from trypsinolysis of WT mtFabH for various digestion times.

A.1.1.2.2 Tryptic digest analysis of the mtFabH- 1 complex:
The comparison of the HPLC profile of trypsin digested mtFabH- 1 complex
(test) and untreated mtFabH (control) showed the appearance of two distinct new peaks at
34 and 41 minutes at 257 nm (Figure X6). To probe the reducibility of these new peaks
(as suggested by the initial reversibility study - Figure X1) we incubated the control
(untreated mtFabH – trypsin digested) and test (mtFabH-1 complex – trypsin digested)
with DTT for 30 minutes and performed HPLC analysis on the resultant reduced peptide
mixture. As evident from Figure X7, the peptide peak at 34 minutes disappeared on
treatment with DTT suggesting the presence of a reducible disulfide bond while the
second peak at 41 minutes stayed unchanged.
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*

*

Min
Figure X6: HPLC analysis of tryptic peptides of mtFabH-Inhibitor 1 complex - The extended HPLC
traces of peptide mixture obtained from trypsinolysis of - a) unmodified mtFabH - λ 204 nm b) mtFabHinhibitor 1 complex - λ 204 nm c) unmodified mtFabH - λ 257 nm d) mtFabH-Inhibitor 1 complex - λ 257
nm. The new peaks are indicated by asterisks.

*

Min
Minin
Figure X7: A Test of reducibility of new peaks from mtFabH-1 complex – Untreated and Inhibitor 1
treated mtFabH peptides were incubated with DTT and subsequently analyzed by HPLC at 257 nm. Figure
a) DTT reduced - untreated mtFabH tryptic peptides and b) DTT reduced – inhibitor 1 treated mtFabH
tryptic peptides. The reducible peak is marked by an arrow and the non-reducible peak is marked by an *.
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A.1.1.2.2.1 Primary sequence of the modified peptide and the residue of attachment:
To further investigate the identity of these new peaks, we purified them on C18
matrix and subjected them to Mass Spectrometric analysis in the Matrix Assisted Laser
Desorption Ionization –Time of Flight (MALDI-TOF) mode. The masses (m/z) of the
two peaks were determined to be 2599 and 1147 Da (34 and 41 minutes respectively) as
shown in Figures X8b and X8c. The unique mass of the first peak (m/z 2599 Da) at 34
minutes corresponded very well with the mtFabH peptide Val16-Arg36 of mass 2523 Da
(envisioned by in-silico tryptic digestion of mtFabH) modified by fragment A (mass 77
Da) of inhibitor 1. To test this hypothesis, we utilized the technique of “product ion
analysis” in MALDI/TOF/TOF mode to analyze the two peptides. Only identical peptides
give exactly the same “fingerprint ions” in this technique in mass spectrometric analyses.
In this technique, the peptide in question is allowed to collide with neutral gas molecules
(often Helium, nitrogen or argon) or air, which result in fragmentation of the peptide into
smaller ions. The key sequence-specific fragment ions seen frequently are the “y-type”
(formed when the charge is retained at C-terminus of fragment ion) and “b-type” ions
(when charge is retained at N –terminus) which can be compared to any peptide to
confirm their identity. Moreover, a modification at any particular residue will alter the
sequence specific pattern of key ions thus potentially revealing vital information about
the modification.
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In order to obtain the proposed (unmodified) peptide fragment Val16-Arg36 of
theoretical mass 2523 Da, we digested the untreated mtFabH with trypsin and performed
direct MALDI/TOF analysis on the entire peptide mixture to search for the parent mass
(Figure X9). The m/z of 2523 Da is selected and subjected to product ion analysis in
MALDI/TOF/TOF mode (Figure X10a). In parallel, the new peak of 2599 Da mass at 34
minutes was subjected to MALDI/TOF/TOF analysis (Figure X10b) and the
fragmentation pattern of both peptides was compared. Comparing Figures X10a and
X10b, the masses of “y” series ions were found to be exactly the same until ion y13 thus
proving that the two peptides at hand were identical. An exact mass differential of 77 Da
on ions “y15” (compared to theoretical fragmentation pattern shown in Figure X10) and
“y16” (MALDI/TOF/TOF spectral data on both peptides) proved that Cys23 is modified
with a 77 Da species. This data clearly identified the peak at 34 minutes in trypsin
digested mtFabH- 1 complex is the “V16 V T N D E I C23 Q H I D S S D E W I Y T R36 “
peptide modified with fragment A of inhibitor 1 linked with Cys23. Additionally, the
reducibility of this peak (as discussed above) also relates well to the proposed disulfide
bond formation between the thiolate of Cys23 and fragment A of inhibitor 1.
The second mass of 1147 Da (peak 2 at 41 minutes in Figure X6) did not correlate
with any of the expected masses of the theoretical digested mtFabH peptides. This could
be a result of aberrant (star) digestion or auto digestion (by trypsin) and thus was not
explored further.
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Figure X8: Identification of new peptides observed on trypsinolysis of Inhibitor 1 treated
mtFabH. The extended HPLC trace (wavelength 257 nm) of peptide mixture obtained from
trypsinolysis of mtFabH -Inhibitor 1 complex (a). The peptides are numbered and the MALDI-MS
spectra of peak 1 (b) and peak 2 (c) are shown.
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Figure X9: Search for proposed parent peptide Val16-Arg36 containing Cys23 (m/z 2523 Da).
a) Theoretical mtFabH peptides on in-silico digestion with trypsin. The proposed parent peak of
m/z 2523 (peptideT4) is underlined in red.
b) Experimental MALDI/TOF mass spectrum of peptide mixture obtained on trypsinolysis of
untreated mtFabH. The arrow indicates the proposed parent peptide T4 of correct mass m/z
2523 Da.
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Figure X10: Relationship between peptide T4 of untreated mtFabH and HPLC peak 1 of
mtFabH-1 digest: Tandem mass analysis of (a) proposed parent peptide T4 m/z - 2523 and (b) new
peptide “1” m/z – 2599 (new peak at 34 minutes in figure 6). The series of y ions as labeled
demonstrate that the sequence of the modified peptide is V16 V T N D E I C* Q H I D S S D E W I
Y T R36) where asterisk denotes the residue modified. The ions y16 show a mass difference of 76.01
Da (2070.9 Da versus 1994.89 Da) corresponding well with addition of fragment A of inhibitor 1.
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A.1.1.2.3 Tryptic digest analysis of the mtFabH- 2 complex:
A comparison of HPLC traces of trypsin digested mtFabH- 2 complex with Control
(untreated mtFabH) showed the appearance of a new peak at 49 minutes (Figure X11).
As outlined above, we probed the reducibility of this new peak by incubating it with DTT
for 30 minutes followed by HPLC analysis of the reduced mixture (Figure X12). The
disappearance of this “new” peak was consistent with a reducible bond, most likely a
disulfide one between a mtFabH peptide and 2.
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*

Min
Figure X11: HPLC analysis of mtFabH-Inhibitor 2 tryptic peptides -HPLC fractionation (257
nm wavelength) of the peptide mixture obtained from trypsinolysis of a) untreated mtFabH and b)
mtFabH treated with excess of inhibitor 2. The new peptide is indicated by an asterisk.

Min
Figure X12: A Test of reducibility of new peaks from mtFabH-2 complex – Untreated and inhibitor 2
treated mtFabH peptides were incubated with DTT and subsequently analyzed by HPLC at 257 nm.
Figure a) DTT reduced - untreated mtFabH tryptic peptides and b) DTT reduced – inhibitor 2 treated
mtFabH tryptic peptides. The new peak is reducible as marked by an arrow.
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To unambiguously identify this new peptide, we purified it and the mass was determined
to be 2739.4 Da by MALDI/TOF (Figure X13b). The mass value of 2739 Da
corresponded very well with modification of Cys23 containing peptide of mass 2523 Da
with fragment A’ (theoretical mass 217 Da) of 2 (refer to chapter 5, Figure 30 for
fragment A’). Finally, the “product ion analysis technique” on “new” peak of m/z 2739
and proposed parent mass of m/z 2523 revealed the identity of both peptides to be “V16 V
T N D E I C23 Q H I D S S D E W I Y T R36 ” with fragment A’ of 2 covalently linked at
Cys23 (Figures X14 a and b).

*

a

min

b

Figure X13: Identification of the new peptide peak observed on trypsinolysis of Inhibitor 2
treated mtFabH. The HPLC traces (wavelength 257 nm) of peptide mixture obtained from
trypsinolysis of mtFabH treated with Inhibitor 2 (a). The peaks are assigned by an asterisk and its
MALDI-MS spectrum is shown in (b).
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Figure X14: Relationship between peptide T4 of untreated mtFabH and new peak of mtFabH-2
digest: Tandem mass analysis of (a) proposed parent peptide T4 and (b) new peptide peak in figure . The
series of y ions as labeled demonstrate that the sequence of the modified peptide is V16 V T N D E I C* Q H
I D S S D E W I Y T R36) where asterisk denote the residue modified. The ions y16 show a mass difference
of 216 Da (2211.0 Da versus 1994.89 Da) corresponding well with addition of fragment A” of inhibitor 2.
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A.2 Method:
A.2.1 Reversibility studies:
Reversibility studies were performed by the standard microcon dilution method.
A solution of the mtFabH (100 µL of 2.6-5.2 µM solution in 50 mM sodium phosphate
buffer, pH 7) was pre-incubated with inhibitor 1 (1.2 µL of 34 mM solution in MeOH;
final inhibitor conc. 400 µM), inhibitor 2 or 3 (2.17 µL of 23 mM solution in MeOH;
final inhibitor conc. 500 µM) for 60 min at 37˚ Celsius. Control experiments containing
mtFabH enzyme were treated with 2.5 µl of MeOH (no inhibitor) in same manner. Two
aliquots from each solution (1 µl each) were withdrawn and the mtFabH activity was
determined under standard assay conditions. The remaining enzyme solutions were
diluted to 500 µl with sodium phosphate buffer, pH 7.0 and concentrated to 50 µl using
50 kDa molecular weight cutoff Microcon concentrator at 8000 rpm on a benchtop
centrifuge. Another aliqout of 450 µl buffer was added and the Microcon step repeated 3
times to obtain the final dilution factor of about 10,000 and enzyme activity was
determined. The enzyme solutions were then treated with DTT (20 mM final
concentration) for 30 min at room temperature, desalted against buffer solution to remove
the excess DTT and the enzyme activity was determined. The enzyme concentration was
determined by Bio-Rad protein assay in all aliquots and equal amounts of enzyme were
used for all assays.
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A.2.2 HPLC analysis of E-I complex:
A solution of 100 µg native WT mtFabH in 50 µl sodium phosphate buffer 50
mM, pH 7.0 was injected onto wide pore 250 X 10 mm C18 RP column, pore size 300 A˚,
particle size 10 µM and the HPLC gradient was run by increasing the acetonitrile conc.
from 0-60 % in 60 minutes at 2 ml/min. For controls, 1 mM solutions of inhibitors 1 or 2
(1.6 µl of 34 mM inhibitor 1 or 2.3 µl of 23 mM inhibitor 2 were added to a final volume
of 50 µl sodium phosphate buffer 50 mM, pH 7.0) were injected onto the C18 RP-HPLC
column and the gradient increase of 1 % acetonitrile per minute was maintained until 100
% acetonitrile (HPLC Buffer B) was achieved and then kept at buffer B for 40 minutes.
For the selection of best conditions for further analyses, various digestion variables (e.g.
native vs. denatured conditions, amount of trypsin to be used and time of digestion) were
also standardized. A 0.74 mg/ml solution of WT mtFabH was treated with guanidium
hydrochloride (final conc. 6 M) in Tris-HCl pH 8.5 and then desalted with sodium
phosphate pH 7.0 using Hitrap desalting column. The protein was concentrated using 50
kDa cutoff Microcon concentrator and then digested with trypsin for 6-8 hrs at 37 ˚C at
200 rpm shaking(ratio 1 : 30 of trypsin : mtFabH) in parallel to native WT mtFabH.
About 100 µg digested peptide mixture was injected onto the C18 column and analyzed as
described above. The amount of trypsin to be used for digestion was determined by
monitoring the extent of digestion at mtFabH : trypsin ratios of 60:1 and 20:1 w/w for 24
hrs. To estimate an appropriate time for digestion, mtFabH was digested with trypsin
(20:1 ratio w/w) at 37 ˚C and 200 rpm shaking and aliquots of 100 µg peptide mixture
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were collected and analyzed at 3, 6, 9, 11 and 24 hours. The peptide traces were
compared with 0 hrs and 24-hrs control (No trypsin added).
A typical standardized trypsin reaction was performed as described below. A
solution of mtFabH (~10uM) in sodium phosphate buffer 50 mM, pH 7.0, 2 mM
dehydroascorbic acid was incubated with ~ 100 µM inhibitor (in methanol) for 1 hr and
then desalted using either Pierce Desalting spin columns or Hitrap desalting columns.
The concentration of methanol in final mixture was kept at or below 1%. Trypsin in 1
mM HCl, pH 3.0 was added to bring the ratio of mtFabH: trypsin to be 20:1 w/w and the
digestion mixture was kept at 37 ˚C for 9-11 hrs with shaking at ~ 200 rpm. A solution of
above digested mixture was treated with 10 mM DTT (final conc.) at 37 ˚C for 1 hr and
then analyzed by RP-HPLC as described below. An amount of 100 µg (typically) of total
peptides was loaded onto widepore 250 X 10 mm C18 column, pore size 300 A˚, particle
size 10 µM and the HPLC analysis was performed at a flow rate of 1 ml/min. The mobile
phases used for HPLC analyses were: buffer A: 97 % water, 3 % acetonitrile, 0.01 %
formic acid; buffer B: 97 % acetonitrile, 3 % water, 0.01 % formic acid. The gradient was
started with 100 % buffer A for 5 minutes and then increased to 60 % B in 60 minutes.
The concentration of buffer A was returned to 100 % in next 5 minutes and 20 minutes of
100 % buffer A was allowed for equilibration step. The peptides were detected using dual
wavelength UV detector set at 204 and 257 nm.
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A.2.3 MALDI-MS and MALDI/MS/MS analysis:
A.2.3.1 Sample preparation:
A solution of 25 µM mtFabH in sodium phosphate buffer 50 mM, pH 7.0, 2 mM
dehydroascorbic acid was incubated with 250 µM inhibitor 1 (in methanol) for 1 hr and
then desalted using Pierce desalting spin columns. Trypsin in 1 mM HCl, pH 3.0 was
added to bring the ratio of mtFabH: trypsin to be 20:1 w/w and the digestion mixture was
kept at 37 ˚C for 11 hrs with shaking at ~ 200 rpm. The control reaction consisted of
untreated mtFabH. Pierce Pepclean spin columns® (C18 resin column) were used to clean
up the digested peptide samples for subsequent MALDI analysis. The following solutions
were prepared as per manufacturer’s guidelines; activation solution: 50% acetonitrile;
equilibration solution: 0.5% TFA in 5% acetonitrile; sample buffer: 2% TFA in 20%
acetonitrile; wash solution: 0.5% TFA in 5% acetonitrile; elution buffer: 70%
acetonitrile. A 15 µl aliquot from both trypsin digested control and test was taken out and
mixed with 45 µl of sample buffer to bring the final concentrations of acetonitrile and
TFA to be 5 % and 0.5 % respectively. The C18 resin was activated with 2 changes of 200
µl activation solution and then equilibrated with 3 changes of 200 µl equilibration
solution. The column was then loaded with 30 µg of peptide mixture and washed with 34 changes of wash solution. Then 2 volumes of 10-µl elution solution were used to elute
the peptide mixture, which was stored in - 20 ˚C until the analyses.
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A.2.3.2 MALDI analysis conditions:
The parent and product ion mass spectra of the tryptic peptides were acquired on a
MALDI-TOF/TOF mass spectrometer equipped with a Nd:YAG laser (355 nm) operating
at 200 Hz (4700 Proteomics Analyzer; Applied Biosystems, Foster City, CA). A
minimum of 1500 shots was averaged for each spectrum. The instrument was externally
calibrated in the positive ion reflector mode with a standard peptide mixture (4700
Proteomics Analyzer calibration mixture; Applied Biosystems) by following the
manufacturer’s instructions. The matrix solution was prepared by dissolving 2 mg of
alpha-cyano-4-hydroxycinnamic acid (CHCA) in 1 mL of 50% acetonitrile/0.1%
trifluoroacetic acid. An aliquot of the tryptic digest was mixed with the matrix solution at
volume ratios of 1:3 to 1:10, depending on sample concentration. A 0.5 µl aliquot of the
sample/matrix mixture was deposited onto a 192-well stainless steel MALDI target plate
and allowed to air-dry. Before sample analysis by mass spectrometry, 2 microliters of
cold water was applied on the deposits and removed within 1 min to remove watersoluble salts and other impurities. Mass spectra were recorded in the positive ion reflector
mode over an m/z range of 800-4000. The ions of interest were selected and subjected to
CID (collision-induced dissociation) using filtered air as the collision gas and a collision
energy set of 1 keV.
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